Review

Bacteria, lipopolysaccharides, amyloid and the role of iron dysregulation in Parkinson’s disease

Marthinus Janse van Vuuren¹, Theodore Albertus Nell¹, Jonathan Ambrose Carr², Douglas B. Kell¹³⁴*, Etheresia Pretorius¹*

¹Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, Private Bag X1 Matieland, 7602, South Africa; mjvanvuuren@sun.ac.za; tnell@sun.ac.za; resiap@sun.ac.za

²Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, Private Bag X1 Matieland, 7602, South Africa jcarr@sun.ac.za

³Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Crown St, Liverpool L69 7ZB, UK dbk@liv.ac.uk

⁴The Novo Nordisk Foundation Centre for Biosustainability, Building 220, Chemitorvet 200, Technical University of Denmark, 2800 Kongens Lyngby, Denmark

* Correspondence: resiap@sun.ac.za (EP); dbk@liv.ac.uk (DBK); jcarr@sun.ac.za (JAC)

Abstract: Neuronal lesions in Parkinson’s disease (PD) are commonly associated with α-synuclein (α-Syn)-induced cell damage that are present both in the central and peripheral nervous systems of patients, with the enteric nervous system also being especially vulnerable. Here we bring together evidence that the development and presence of PD depends on specific sets of interlinking factors that include neuro-inflammation, systemic inflammation, α-Syn-induced cell damage, vascular dysfunction, iron dysregulation, gut and periodontal dysbiosis. We argue that there is significant evidence that bacterial inflammasogens fuel this systemic inflammation, and might be central to the development of PD. We also discuss the processes whereby lipopolysaccharides may be involved in causing nucleation of proteins, including of α-Syn. Lastly, we review evidence that pre-and probiotics, as well as antibiotics and faecal transplant treatment might be valuable treatments in PD. A most important consideration, however, is that these therapeutic options need to be validated and tested in randomized controlled clinical trials. However, targeting underlying mechanisms of PD, including gut dysbiosis and iron toxicity, have potentially opened up possibilities of a wide variety of novel treatments which may relieve the characteristic non-motor deficits of PD, and may even slow the progression and/or accompanying gut-related conditions of the disease.

Keywords: Bacteria; Lipopolysaccharides; Gingipains; Amyloid and Parkinson’s disease; α-Synuclein
1. Introduction

The global prevalence of Parkinson’s disease (PD) during 2016 reached 6.1 million [1]. In the United States of America, Canada and Europe the prevalence is projected to increase by approximately 92% by 2050 [2], involving an increased burden on global healthcare [3].

α-Synuclein (α-Syn) is the principal component of Lewy bodies (LBs), which are the pathological hallmark of PD and other related conditions [4]. This group of illnesses, termed the synucleinopathies, includes multi-system atrophy, dementia with Lewy bodies and pure autonomic failure. α-Syn-stained inclusion bodies and fragments of neurons are detectable in many otherwise healthy individuals at the time of post mortem examination and detailed histological examination has led to conclusion that the initial lesions of PD are thought to occur in the medulla, in the region of the dorsal motor nucleus of the vagal nerve, and also in the olfactory bulb [5-7]. Neuronal lesions in PD, commonly associated with α-Syn-induced cell damage are therefore present both in the central- and peripheral nervous systems (CNS or PNS) of PD patients [8], with the enteric nervous system also being especially vulnerable [9]. In PD patients, LBs are also observed in non-dopaminergic neurons outside of the basal ganglia, in areas such as the glossopharyngeal-vagal complex, coeruleus-subcoeruleus complex, caudal raphe nuclei, gigantocellular reticular nucleus and olfactory pathways [5]. The knowledge that LBs consist mainly of misfolded amyloid forms of α-Syn has therefore shaped investigations in the field of PD research to adopt a “synuclein-centric and neuro-centric” approach, predominantly focusing on the central nervous system (CNS). However, recent studies have challenged this neuro-centric approach [10].

Of particular interest in PD is the prion hypothesis in which it is postulated that fragments of the protein α-Syn may lead to the formation of progressive accumulation of amyloidogenic protein material [11, 12]. In accordance with this theory, PD is characterised by a rostro-caudal progression of deposition of α-Syn, associated with neuronal loss, and with positive staining for α-Syn of LBs and Lewy neurites [6]. Involvement of both the olfactory bulb and the medulla is explained by a proposed dual-hit mechanism, involving anterograde progression of pathology from the olfactory system into the temporal lobe, and retrograde progression to the brainstem from the gut following ingestion of a neurotropic pathogen [13, 14]. α-Syn staining material is present in patients with PD in a number of tissues outside the brain and spinal cord and is present before the diagnosis is made [15, 16]. It is also noteworthy that non-motor features such as rapid eye movement (REM) sleep behaviour disorder [17], constipation [18], loss of the ability to smell, and sleep disorders may precede the appearance of tremor and other classical features of PD by as much as two decades or more. Gastrointestinal symptoms are common, and can precede motor symptoms and clinical PD diagnosis [19].

Although PD research and clinical perspectives have focused on genetics and efforts to remove or prevent the distinctive α-Syn-containing cytoplasmic inclusions (LBs), little progress has been made to prevent progression of disease or to cure PD. A number of PD genes have been identified as playing a role in PD aetiology [20]. Even collectively, mutations in these six genes explain only a limited number (3%-5%) of sporadic disease occurrences [21]. (For an overview of PD genes and dopaminergic neurons, see [20]). Over the past years, researchers have published significant numbers of papers that suggests that the motor effects and the progressive degeneration and loss of preferential dopaminergic neurons in the substantia nigra seen in PD patients, might be related to factors other than a predominantly genetic cause. Recently, there has been increasing focus on investigating the link between increased iron and copper levels (both systemically and in the brain) [22], the role of the microbiome, and how dysregulated circulating inflammatory biomarkers, including those originating from bacteria, might all interplay in PD pathology [19].

In this paper, we aim to bring together evidence that the development and presence of PD depends on specific sets of interlinking factors. Together with neuro-inflammation, patients with PD also have systemic inflammation, with many cellular signals pointing to major vascular dysfunction. We discuss published evidence that PD is both associated with and driven by dysregulated circulating inflammagens (an irritant that elicits both oedema and a cellular response of inflammation), and cytokines. Furthermore, there is significant evidence that bacterial
inflammasens fuel this systemic inflammation, and might be central in the development of PD [3, 23-28]. There are a number of papers suggesting altered immune activation in PD [29-32], and also papers demonstrating altered immune activation in PD populations [33-35]. There are also experimental works indicating that inflammatory action can induce PD-related phenotypes [36-39].

The immune response in PD, which is proposed to occur early, involve peripheral and brain immune cells, eventually evolve as neuronal dysfunction progresses, and is likely to influence disease progression [40]. Central to these immune changes in PD is the interplay between the microbiome-gut-brain axis [25, 41-43].

Since these changes are taken to be deterministic [44], we furthermore point out that, together with genetic predisposition and epigenetic changes, the only way to address this extremely significant healthcare dilemma is to find the origin of these inflammasens and the reason for immune activation in PD. We argue that this origin is microbial. Central to its cause might be microbiome dysregulation, translocation, and co-morbidities including periodontitis and gingivitis. For an overview, see Figure 1.
Figure 1: An overview of Parkinson’s Disease: what do we know from the literature? 1) Traditional focus on a synuclein-centric and neuro-centric approach. Shift in focus to the role of 2) lifestyle and 3) environmental factors that result in 4) innate immune activation.
2. A mind-shift in Parkinson’s disease research

2.1. Parkinson’s disease, iron and chronic systemic inflammation

Chronic inflammation, the circulation of pro-inflammatory molecules, and the dysregulation of innate immune responses can contribute significantly to both the onset and progression of neurodegeneration in PD [32, 45-52]. Both pathological levels of iron and oxidative stress are of importance in PD neuro-inflammation. The spectrum of iron dysregulation in PD includes iron storage, uptake and release [53]. Iron accumulation in the substantia nigra is considered one of the fundamental reasons for dopaminergic neurons dysfunction [20, 54-57]. An important iron compound in dopamine and norepinephrine neurons is the neuromelanin-iron complex [53, 58]. Interestingly, neuromelanin is a strong iron chelator [53]. In PD there is a loss of neuromelanin in the substantia nigra, and this could lead to enhanced calcium messaging, followed by formation of reactive oxygen species (ROS) and eventually neuronal apoptosis [59]. Serum ferritin is also upregulated in the circulation of PD individuals [60]. It has been well documented that the absence of free iron restricts the growth of pathogens. Here we point out the corollary – that the presence of free iron allows their proliferation (and hence translocation). In particular, the cytotoxicity caused by invading microbes causes the release of iron that allows their (limited) proliferation and the release of more inflammagenic bacterial products.

Figure 2, shows the important role of iron, mitochondria and lysosomes in substantia nigra neurons (adapted from Funke and co-workers (2013)) [20]. Physiological levels of iron and the presence of oxidative stress are not only present in the brains of PD patients but also in their circulation. In PD patients, excessive systemic inflammation also occurs [24, 45], simultaneously exacerbating and perpetuating neuro-inflammation and may also be the trigger of the inflammatory events ongoing in the brain. There is an increasing recognition of the involvement of Toll-like receptors (TLRs) in neuronal degeneration as cells of the nervous system express TLRs; and that these TLRs are activated by α-synuclein. The activation of these TLRs induces an inflammatory response that precedes neuronal loss [25]. In addition, interleukin-1 (IL-1), can be synthesized and released by activated microglia, and could possibly cause dopaminergic neurodegeneration leading to PD [61]. Activated microglial cells have also been shown to be involved in the secretion of TNF-α thereby contributing towards the progress of PD [62]. In addition, α-syn also induces TNF-α [63]. See Table 1 for selected references regarding systemic inflammatory mediators and numerous papers reporting on a dysfunction of iron metabolism in PD.
**Figure 2**: Interactions in a PD neuron between mitochondria, lysosomes, iron, α-Syn production and ultimately proteasomal dysfunction, oxidative stress and apoptosis (adapted from [20]). The figure illustrates the interplay between mitochondria and lysosomes during the apoptotic cell death that characterises the death of neurons in the substantia nigra that is the hallmark of PD. The location of receptors like the TLR and IL-1 receptors and the metal ion transporter 1 are shown. These receptors and transporter are known to bind bacterial inflamagens, IL-1 and Fe^{2+}. These molecules play a fundamental role in the downstream activation of inflammation and oxidative stress, and ultimately play a crucial role in α-Syn and Lewy body formation.

**Table 1**: Selected references showing evidence of systemic mediators of inflammation in Parkinson’s Disease.

| Mediators of inflammation                                                                 | References                  |
|------------------------------------------------------------------------------------------|-----------------------------|
| Activated microglia and upregulation of inflammatory mediators systemic and CNS inflammation, chemokines, (ROS) and oxidative stress | [60, 64-68]                  |
| Various cytokines including interleukin (IL)-1β, IL-2, IL-6, IL-10, tumour necrosis factor (TNF)-α, interferon (IFN)γ, Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted (RANTES) and C-reactive protein (CRP) | [45, 69-74]                  |
| Increased cluster of differentiation (CD)4+ T-cells indicating peripheral lymphocyte-activation | [75, 76]                    |
Nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX2) in post-mortem PD brains [77, 78]

Enteric inflammation increased mRNA and mRNA associated with glial markers. Gut-brain axis and intestinal inflammation in PD [9, 42, 43, 79, 80]

Enteric inflammation and levels of stool immune factors [81, 82]

Bacterial inflammagens like LPS and bacterial proteases like gingipains [45, 83-85]

Iron dysregulation [20, 50, 55, 56, 86-96]

3. An integrated physiological systems disease

The question that now arises is if there is any substantial evidence that pathological iron levels, and increased presence of inflammatory biomarkers (both in circulation and the brain), could originate from somewhere else than the PD brain. The quest for the origin and the trigger of PD pathology, has led researchers to search for systemic hallmarks that characterize PD patients [45, 69-74]. Data suggest that most PD patients may suffer from gut dysbiosis and other conditions that allow bacterial translocation. The origin of dysregulated circulating inflammatory biomarkers could therefore involve bacteria, and particularly their inflammagens, entering the body via gut dysbiosis and translocation (when microbes appear in places other than their normal location) [19]. These inflammagens might in fact contribute significantly to the increased iron levels and circulating cytokines in PD [39, 54, 57, 63, 97].

3.1. A continuum of pathological events or the distinct events hypothesis?

The etiology of PD is a complex process and the evidence in persons with PD (with or without REM behavioural disorder) indicates that degeneration may start either in the CNS or in the peripheral nervous system (PNS). A continuum of pathological events or the “chicken or egg” hypothesis is therefore not a straight forward assumption. A recent 2019 paper discusses the hypothesis of brain-first or gut-first in the development of PD, where the authors argue that it is hypothesized that PD can be divided into various subtypes, as either PNS-first and a CNS-first subtype [98]. Central to the extent of involvement of bacteria, and the presence of gut dysbiosis and translocation in PD, is the question of autonomic dysfunction, i.e. orthostatic hypotension, constipation, bladder disturbances, and sexual dysfunction [99]. These symptoms precede neuromotor symptoms and are strongly associated with impaired activities of daily life and dementia during later stages of the disease [100, 101]. Dysautonomic symptoms are frequently found in the various α-synucleinopathies, including PD [102]. Autonomic dysfunction affects the enteric nervous system, resulting in constipation [26]. An important concept to consider, is whether dysbiosis and translocation, are causes of autonomic dysfunction and α-synucleinopathies, or whether neuro-inflammation causes a spill-over peripheral autonomic dysfunction. Evidence that might provide an answer to this critical question may be found in the timing of the various pathologies. Already in 2001, Abbot and co-workers suggested that further studies are needed to determine whether constipation is part of early PD processes or is a marker of susceptibility or environmental factors that may cause PD [18]. In PD patients, α-Syn inclusions have been detected in colon biopsies up to eight years before the onset of motor symptoms of PD and it has been argued that the presence of extracellular α-Syn is associated with acute and chronic inflammatory conditions of the intestine [103, 104]. It may be worth noting here that in individuals without PD may also have intestinal α-Syn inclusions, which can also be detected [105]. The specificity and sensitivity of colonic biopsies for the detection of pathological α-Syn inclusions is therefore conflicting across various research. A recent prospective cohort study also showed that patients presenting with pure
autonomic failure are at high risk of pheno-converting to a manifest neuro-synucleinopathy [106]. Sampson and colleagues demonstrated that faecal transplantation of gut microbiota from PD patients enhanced α-Syn-mediated motor dysfunction in a mouse model of PD [107]. The authors further found that germ-free animals displayed significantly fewer α-Syn inclusions in the CNS, indicating that gut microbiota are required for α-Syn aggregation and formation of the hallmark inclusions seen in PD.

In their hypothesis, Borghammer and Van Den Berge (2019) [98] suggest that PD associated with the PNS-first hypothesis is tightly associated with REM sleep behaviour disorder during the prodromal phase and is characterized by marked autonomic damage before involvement of the dopaminergic system. In contrast, the CNS-first phenotype is most often REM sleep behaviour disorder-negative during the prodromal phase and characterized by nigrostriatal dopaminergic dysfunction prior to involvement of the autonomic PNS [98]. The current available evidence points to intestinal involvement, but also it should be highlighted that there is an absence of longitudinal research studies. Such studies need to be conducted to provide appropriate data with strong evidence to support this hypothesis. According to our understanding of the sequence of events, evidence points to an intestinal involvement, followed by systemic inflammation and then the occurrence of neurological PD symptoms (see Figure 3). It can furthermore also be presumed that many diseases, including PD, can be caused by a positive feedback, and that this might lead to overwhelming of homeostatic mechanisms. In this case the positive feedback mechanism (viz. A causes B then B causes more A etc.), is dysbiosis/translocation and amyloid formation and deposition. In Figure 3, we argue that this positive feedback mechanism is present in PD, and it is between α-Syn aggregation and autonomic dysfunction. There is significant evidence of gut dysbiosis in PD, as reviewed in the following paragraphs.
Figure 3: Parkinson’s disease: a continuum or distinct events hypothesis? The condition is characterized by the presence of 1) predisposing genetic, environmental and lifestyle factors that together contribute to both 2) systemic and neuro-inflammation. 3) Autonomic dysfunction and a 4) dysregulated bidirectional signalling system and 5) α-Syn aggregation are associated with 6) motor and dopaminergic neuron dysfunction. We argue that there is a positive feedback mechanism, between 5) α-Syn aggregation, and 3) autonomic dysfunction.

4. Gut dysbiosis and Parkinson’s disease

The gastrointestinal tract can communicate with the central nervous system by several mechanisms, including hormones, cytokines and microbial metabolites via circulation, as well as direct neural circuits via the autonomic nervous system (vagus nerve) [108]. Dysregulation of the bidirectional signalling system (the gut-brain-axis, also known as the gut-microbiota-brain-axis or the microbiome-gut-brain axis), is well-known in PD. Parkinson’s disease patients have a significantly higher incidence of comorbid gastro-intestinal dysfunction, with between 60% and 80% of patients suffering from constipation [109], and intestinal inflammation [9]. Gastro-intestinal dysfunction is therefore a very well-known accompaniment to PD [110, 111] and also precedes the onset of motor symptoms by several years [112]. It has been shown that faecal and mucosa-associated gut bacteria of PD patients differ substantially from healthy individuals [84, 112, 113]. Nuzum and co-workers review literature that discussed gut microbiota differences between PD groups and controls, were variations may potentially be the cause of PD pathophysiology [19]. However, the authors noted that differences in methodologies may be problematic [19]. Parkinson’s disease-associated constipation has also been found to correlate with α-Syn accumulation in the enteric nervous system, resulting in
local inflammation, oxidative stress and increased intestinal permeability [114, 115]. A significant body of work has therefore implicated gut dysbiosis as a major contributory factor to the constipation observed in PD patients.

We suggest that α-Syn aggregation may originate in the gut and propagate via the vagus nerve to the brain. This hypothesis is supported by reports of α-Syn inclusions being observed in the enteric nervous system, including the vagal nerves [7], sometimes years before the onset of the first motor symptoms [116]. Injection of α-Syn fibrils into the gut tissue of healthy rodents also induced pathology in the vagus nerve and brainstem, indicating that misfolded α-Syn propagates from the gut to the brain via the vagus nerve [117]. It has also been shown that vagotomised subjects are at a lower risk of developing PD [118]. An important consideration during gut dysbiosis in PD are the effects of gut-derived bacteria escaping from the gastrointestinal tract into the blood as a result of gut dysbiosis, along with their shedding of endotoxins into the systemic circulation, which may constitute a trigger event in the development of PD and other neurodegenerative disorders [45, 119]. Although there is also evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in animal models [120]. However, these models report varying results [121-123].

4.1. Bacterial inflammmagens

Gut dysbiosis is typically associated with an increase in Gram-negative bacteria such as E. coli and H. pylori, which are known to secrete a variety of pro-inflammatory molecules [115, 124]. Bacterial inflammmagens can act as both cytotoxins and neurotoxins, which disrupt the homeostatic functioning of cells in circulation and tissues [125, 126]. Microbes shed their respective inflammmagens (endotoxins) in response to different physiological and environmental cues, potentially resulting in a broad spectrum of deleterious effects [44, 127]. These include both systemic inflammation and neuro-inflammation as well as impaired gut barrier function [44, 128]. Bacterial inflammmagens implicated in inflammmation may include proteolytic enzymes such as carbonic anhydrases, peptidyl deiminases and gingipains, as well as bacterial appendages like curli fibres and fimbrae, LPS, or lipoteichoic acid (LTA) [83, 129-132]. There is also evidence that curli can also accelerate synuclein pathology in rat and worm models [133] and in mice models [97]. Furthermore, bacterial amyloids have the potential to influence cerebral amyloid aggregation, and neuroinflammmation, and microbiota-associated proteopathy and neuroinflammation may be a promising area for therapeautic intervention [134].

Bacterial inflammmagens may also indirectly contribute to the onset and progression of PD through their activation of peripheral immune cells, including macrophages, monocytes, microglia and astrocytes, which can penetrate the blood brain barrier (BBB) and contribute to neuro-inflammation. They may also directly contribute to PD pathology by inducing structural alterations in proteins, favouring a transition from α-helices to β-sheet-rich amyloid fibrils [135]. In the brain, the resulting aggregation of these amyloid proteins leads to formation of the characteristic LBs observed in PD, and in the blood, amyloid fibrin(ogen) causes hypercoagulation, a recently discovered accompaniment of PD pathology [45]. A bacterial inflammmagen that is of particular interest is bacterial cell membrane LPS, which are large molecules consisting of an inner hydrophobic lipid A domain, a non-repeating oligosaccharide ‘core’, and a distal polysaccharide chain known as an O-antigen which determine the strain’s serology [136]. The lipid A domain is typically described as the site of the molecule that is most inflammmagenic [135]. We do recognise that there are commensal gut bacteria-derived LPS which may be less immunogenic [137]. However, in the context of this paper, we refer to the LPSs that can act as potent inflammmagens.
4.2. Contribution of Lipopolysaccharides to Parkinson’s disease

4.2.1. Lipopolysaccharides (LPS) as a potent inflammmagen

Although there are hypotheses like the hygiene hypothesis [138] that suggest that early exposure to specific microorganisms and parasites in infancy benefits immune system development and confers protection against allergic and autoimmune diseases [139], many papers report the detrimental effects of LPS. However, although LPSs and their effects are not homogenous, it should be noted that microbiome-derived LPS could possibly impact long-term immunosuppressive mechanisms in more complex ways than has been previously thought. At a cellular level, LPS acts via the toll-like receptor 4 (TLR4), activating NF-κB and transcription of pro-inflammatory cytokines and proteins including pro-IL-1β and NLRP3 [140, 141]. However, it is initially extracted from bacterial membranes by serum LPS-binding protein (LBP). LBP then transfers LPS to CD14, where CD14 then disaggregates LPS complexes and present the LPS to TLR4 [142]. Upon TLR4 binding to LPS, multiple signaling components are activated including NF-κB [143-146]. Intracellular LPS can also activate the non-canonical NLRP3 inflammasome pathway via caspase-11 (caspase-4 or -5 in humans), leading to caspase-1 activation [85, 147]. LPS can thus act on both TLR pathways, as well as inflammasome pathways. Therefore, the damaging effects of LPS are underscored by evidence that it can cause misfolding and aggregation of α-Syn [148, 149]. LPS, due to its strong inflammmagenic properties, is also regularly used to produce in vivo models of both PD and Alzheimer’s disease (AD) [150-152], as well as other inflammatory diseases such as pre-eclampsia [153-155].

Microglia activation is a histopathological hallmark of PD [156]. It has also been previously demonstrated that LPS can activate microglial cells, suggesting that LPS is involved in the development of neuro-inflammation [157, 158]. In addition, LPS is also considered a potent immune stimulator and has been shown to bind to several receptors such as CD14, a glycoprotein expressed in monocytes, and/or macrophages [142]. It has also been shown to form complexes with LPS-binding protein and TLR4 [158]. Once bound, LPS activates host cells through several signalling pathways and upregulated cytokines, including Nuclear factor-κB (NF-κB), TNF-α, IL-1β, IL-6, IL-12 and iNOS [159, 160]. Cytokines such as IL-1β and IL-6 induce the production and secretion of serum amyloid A (SAA) in the liver, specifically acute phase SAA1 and SAA2. During the acute-phase immune response, SAA contributes to the inflammatory response by attracting immune cells, activating the transcription factor NF-κB, and stimulating pro-inflammatory cytokine production [161].

Systemic injection of LPS has also been shown to cause damage to the BBB of recipient animals, leading to the subsequent crossing of peripheral cytokines into the brain [162-164]. LPS was also found to induce functional changes in microglia, suggesting that it will induce blood brain barrier dysfunction due to ROS via nicotinamide adenine dinucleotide phosphate (NADPH) oxidase [165]. LPS-activated microglia can also release cytokines like IL-1β, IL-6 and TNFα, resulting in an increased expression of inducible nitric oxide synthase (iNOS) and production of ROS [166]. Interestingly, it was found in a rat model that the substantia nigra had the highest density of microglia, and that these microglia were particularly vulnerable to LPS damage [156]. Low doses of LPS were also found to induce secretion of cytokines, and thereby increased vulnerability of dopamine neurons in a rat model [167]. Inflammation induced by LPS also increases α-Syn entry into the brain via the BBB [168], possibly driving LB formation (this study was an animal study). Interestingly, in a 2015 study, Hasegawa and co-workers also showed in 52 PD patients that LPS-binding protein levels were lower than in controls [84]. Lower levels of LPS-binding protein in PD might be related to its binding of increased LPS in circulation or might indicate indicating less LPS neutralisation [140]. In a 2020 paper from Wijeyekoon and co-workers also directly demonstrate elevated serum endotoxin in PD,
particularly in patients with increased risk for early dementia [85]. LPS in circulation therefore directly or indirectly leads to neurodegeneration by inducing a strong inflammatory response, causing degradation of the BBB, inflammation and oxidative stress in the CNS, and the stimulation of α-Syn misfolding and aggregation into LBs.

**4.2.2. Formation of nucleated molecular intermediates as induced by LPS**

It has been suggested that LPS may change the structure of (healthy) proteins, whereby it may induce the formation of nucleated molecular intermediates. Nucleation is a process whereby phase transitions are initiated in proteins [169]. In the context of protein biophysics, nucleation is used to describe a process whereby supersaturated protein solutions form insoluble macromolecular protein aggregates. Although a complicated biophysical process, nucleation can be described as a primary and a secondary process and these processes were already described in the 1960s [170]. Nucleation therefore occurs by two pathways, the first being a fibre-independent (primary) pathway and the second a fibre-dependent (secondary) pathway [171]. Primary pathways, such as homogeneous nucleation, generate new aggregates at a rate dependent on the concentration of monomers alone and independent of the concentration of existing fibrils [170, 172]. Secondary pathways are the complementary mechanisms, that generate new aggregates at a rate dependent on the concentration of existing fibrils [172]. The latter class can be subdivided into monomer-independent processes, such as fragmentation [171-173] with a rate depending only upon the concentration of existing fibrils, and monomer-dependent processes, such as secondary nucleation. LPS may be involved in both primary and secondary nucleation reaction pathways.

In AD for example, pathological protein fibril formation where protein is changed to amyloid fibrils, is well known and these fibrils are characterised by a highly ordered cross-β conformation [174]. The generation of toxic oligomers during the aggregation of the beta-amyloid (Aβ) peptide Aβ42 into amyloid fibrils and plaques is an example of a form of nucleation [172]. Cohen and co-workers showed that once a small but critical concentration of amyloid fibrils has accumulated, the toxic oligomeric species are predominantly formed from monomeric peptide molecules through a fibril-catalysed secondary nucleation reaction. The authors argued that such a secondary nucleation mechanism is seen in Aβ, rather than through a classical mechanism of homogeneous primary nucleation [172]. This catalytic mechanism, insoluble amyloid fibrils and the generation of diffusible oligomeric aggregates, are possibly the neurotoxic agents in AD. In PD, α-Syn is also a well-known example of protein conformational changes, and primary nucleation was also noted in α-Syn protein [175]. (Although not the focus of this review, we also note that both Aβ and α-Syn have antimicrobial properties and there are experimental evidence for this happening, as shown in mouse [176] and worm models [177]. There is also evidence that Aβ oligomers have potent, broad-spectrum antimicrobial properties by forming fibrils that entrap pathogens and disrupt cell membranes [177]. Furthermore, it was also shown that α-Syn exhibits antibacterial activity against *E. coli* and *Staphylococcus aureus* [178]).

LPS is also implicated in protein nucleation. LPS can modulate α-Syn amyloidogenesis through the formation of intermediate nucleating species [23]. Bhattacharyya et al. demonstrated that *E. coli*-derived LPS modulates α-Syn aggregation *in vitro* by forming intermediate LPS-α-Syn complexes [23]. These intermediate complexes might be responsible for the PD-associated pathological effects of α-Syn amyloids [23]. The authors furthermore proposed that N-terminal-mediated anchorage of the amphipathic molecule, results in the eventual partial internalisation of the “fibrillating” (fibril forming) motif, situated in the hydrophobic acyl region of the LPS molecule. It therefore appears that LPS can modulate the overall aggregation kinetics of α-Syn in a concentration-dependent manner. Thus, the direct molecular interaction with LPS results in the modulation of the protein’s conformation into alternative nucleating forms that are morphologically and functionally distinct from the wild type α-Syn conformers. Most importantly the characterization of the epitope of interaction in the LPS-mediated nucleation possibly allows for novel targets in the therapeutic interventions.
LPS may also induce amyloid forms of the clotting protein fibrin(ogen) during blood clotting, and significantly contributes to systemic inflammation and coagulopathy [128, 135, 179]. Our research group has also shown that LPS may interact with the plasma protein fibrin(ogen), resulting in protein misfolding. These protein changes can be visualized using amyloid stains, e.g. thioflavin T and newer fluorescent markers, known as Amytrackers [128, 135, 179]. Figure 4 shows the diagram and micrographs from Bhattacharyya and co-workers [23], as well as an example from our previous work [45, 128, 135, 179]. The intermediate LPS-α-Syn-complexes shown by Bhattacharyya and co-workers look very similar to the LPS-fibrinogen-complexes. Bhattacharyya and co-workers’ 2019 results might therefore suggest that α-Syn fibrillation could possibly form part of a neuro-immunological response to bacterial inflamagens.

**Figure 4: A and B**) Courtesy of [23]; (permission and license of usage were granted by publisher and supported by authors). A) Schematic representation of the orientation of α-Syn in aqueous solution (left) and in the presence of LPS micelle (right). B) Transmission electron microscopy (TEM)
images showing morphologically distinct α-Syn fibrils at 1:1 LPS concentration at two different time points (t = 3 and 120 h). Scale = 200 nm. C) Confocal microscopy images of fibrin networks formed from purified fibrinogen (with added Alexa488 fluorophore) incubated with and without LPS from *P. gingivalis*, followed by addition of thrombin to create extensive fibrinogen clots (unused raw data from [45]).

4.3. Oral microbiota translocation in Parkinson’s disease

Periodontitis and gingivitis have also been implicated in PD [27, 180, 181]. Specifically, periodontal inflammatory disease constitutes another point of entrance for bacteria in facilitating translocation. It was initially hypothesised that PD patients develop increased periodontal pathology, as a result of the progressive loss of self-care ability and fewer dental attendances [182, 183]. However, Liu and co-workers reported, in a retrospective cohort study, that there is an increased risk of developing PD following chronic periodontitis [184]. Chen and workers also reported that individuals with periodontal inflammatory disease had a 1.4-fold higher chance (adjusted hazard ratio) of developing PD [185].

One of the Gram-negative bacteria that has been implicated as a causative agent in periodontitis and gingivitis is *Porphyromonas gingivalis* (*P. gingivalis*), and its inflamagens have been associated with the development of various inflammatory conditions [186-190]. It is mainly a bacterium from the mouth, however, after oral administration in animal studies, it may also induce gut dysbiosis and impaired gut barrier function [191], and can induce systemic inflammation [192]. In an attempt to elucidate the underlying mechanisms of how oral bacteria alter the gut microbiota, researchers performed serum metabolome analysis on mice treated with *P. gingivalis* [193]. Recipient mice showed elevated serum amino acids (alanine, glutamine, histidine, tyrosine and phenylalanine) [193], suggesting an increase in bacterial communities which yield these metabolites. There is therefore an increased risk of developing various diseases where there is *P. gingivalis* presence, and that the bacterium’s effects might be mediated in part by alteration of metabolic profiles in diseases, particular metabolic diseases [193].

4.3.1. Gingipains as potent inflamagens from *P. gingivalis*

Gingipains (toxic bacterial proteases) are virulence factors produced by *P. gingivalis* [189]. Gingipains consist of Arg-gingipain (Rgp) (RgpA and RgpB), and Lys-gingipain (Kgp), and exist in both cell-associated and secreted forms which play a central role in the virulence of this organism [194]. Gingipains were also found in the brains of AD patients, and were implicated in the development of AD [189]. Recently, we reported on gingipains in the blood of PD patients, with a similar hypercoagulation effect as for LPS [45]. Gingipains may potentially also enter via the nasal cavity, from where it may potentially journey via the olfactory bulb. This process may potentially be underpinned by the proposed dual-hit mechanism, involving anterograde progression of pathology from the olfactory system into the temporal lobe, and retrograde progression to the brainstem [13, 14]. We suggest that the presence of the same inflamman in either AD or PD pathologies, is closely associated with genetic predisposition and epigenetic changes. These inflammanns also occur in different locations of the CNS and hence lead to different diseases. The data illustrating gingipains’ ability to induce hypercoagulation, as well as to infiltrate brain tissue and activate amyloid protein formation, make these bacterial proteases promising candidates for study when attempting to elucidate the etiology and progression of PD. Figure 5 provides an overview of the proposed gingipain activities following translocation into the circulation.
Figure 5: An overview of the effects of the translocation of bacterial gingipain into the circulation: 1) Immune evasion brought about by proteolytic degradation of antibodies, cytokines and immune receptor CD14. 2) Proteolytic degradation of transferrin (TFN) and haemoglobin (Hgb). 3) Hypercoagulation caused directly by contact of platelets with gingipain proteases, and 4) amyloidogenesis, resulting not only from direct contact of neurons with gingipain proteases, but also indirectly as a result of increased iron levels which occur due to the degradation of iron-containing proteins.

5. Therapeutic possibilities and pharmaceutical interventions

5.1. Antibiotics and probiotics

The effective use of therapeutics such as antibiotics (and probiotics) in the treatment of PD and its associated gut-related issues can only be rigorously assessed in randomized double-blind controlled clinical trials. Unfortunately, most papers that report on the use of antibiotics and probiotics are based on limited data or case studies. However, both antibiotics and probiotics usage have been suggested for the treatment of PD, and particularly for the restoration of the gut microbiome in PD patients. Probiotics were found to possibly alter the clinical progression of PD [195] and alleviate constipation and gut-related issues [196, 197]. Furthermore, probiotics, prebiotics and synbiotics are being examined that might influence the gut-brain axis by altering gut microbiota composition, enteric nervous system, and CNS [198] and may play important roles in the regulation of dysbiosis in PD [199].
Antibiotics as treatment regime in PD have mostly focussed on targeting constipation and gut dysbiosis. Antibiotics such as rifaximin with poor systemic absorption may be used to treat small bowel bacterial overgrowth, which is also observed in PD [200]. Particularly, minocycline may have some neuroprotective activity in various experimental models including PD, [28, 201, 202]. Minocycline and its effects as a neuro-protecting antibiotic, are related to inhibition of mitochondrial permeability and the suppression of microglial activation [203]. Also, there is a growing body of evidence to suggest that minocycline elicits neuroprotective effects in PD, particularly because it restores gut microbiota balance, due to the reduction of Firmicutes and Bacteroidetes bacteria [25]. In addition, minocycline exerts anti-inflammatory effects that possibly may mediate its neuroprotection [204].

Rifampicin, another antibiotic known to exert multiple neuroprotective functions is suggested as potential treatment regime for PD [205, 206]. Rifampicin, and its derivative rifampicin quinone, were found to reduce microglial inflammatory responses and neurodegeneration induced in vitro by α-Syn fibrillary aggregates [207]. Rifampicin might also reduce the cytotoxicity by promoting SUMOylation of α-Syn [208]. SUMOylation refers to when a small ubiquitin-like modifier (SUMO) moiety is covalently linked to a lysine residue in the target protein. Dysregulation of SUMOylation of extranuclear proteins is strongly implicated in neurological and neurodegenerative diseases [209], including PD [210] Although there is great potential for treating PD using antibiotics, certain antibiotics, including tetracyclines, sulphonamides and trimethoprim have been associated with increased risk of PD [211]. The exact mechanisms of action of these antibiotics in the treatment of PD is an important research question that needs to be answered. In particular, longitudinal studies are need to determine how affective antibiotics are to successfully treat the comorbidities of gut dysbiosis, gingivitis and periodontitis, as well as constipation; or indeed to stop the progression of the disease.

5.2. Iron chelation

Several iron chelator molecules have been suggested as sequestering agents for unliganded iron [212, 213]. Neuromelanin has been shown to protect dopaminergic neurons from iron-induced damage, even in conditions of iron overload, by forming stable complexes with unliganded iron [214]. Youdim and colleagues (2004) developed brain penetrable compounds, the VK-28 series, which are known to have iron chelating properties similar to or even better than the well-known iron chelator desferrioxamine (desferal). An important characteristic of an iron chelating molecule should be its ability to inhibit monoamine oxidase (MAO). MAO generates H2O2, which interacts with ferrous iron to form reactive hydroxyl radicals via Fenton chemistry [56, 215-217]. The Fenton reaction (Fe2+ + H2O2 → OH− + HO•) is a non-enzymatic reaction that obeys mass action law, meaning that the rate of hydroxyl radical production is directly proportional to the amount of Fe2+ in the cell [218, 219]. Unfortunately, desferrioxamine has relatively poor MAO inhibition [220]. In contrast, VK-28 has been shown to have good MAO inhibitory and iron chelating properties [220]. More recently, VK-28 was also shown to be protective against iron toxicity and less toxic than deferoxamine [221].

Clinical trials of iron chelation in the treatment of PD have paid specific attention to deferiprone as a promising pharmaceutical intervention. Papers showing possibly promising efficacy with regard to neurodegeneration include [219, 222, 223]. However, little longitudinal clinical data is available that shows significant results, suggesting its efficacy in symptomatic improvement of pausing of disease progression. During a randomised trial of deferiprone administration to patients with early-stage PD, over a period of six months, decreased iron concentrations in the substantia nigra pars compacta (SNc) were found [212]. Suspension of treatment resulted in the restoration of the elevated iron levels, suggesting a return to the pathological iron dyshomeostasis which might underlie PD. A phase 2 clinical trial of deferiprone by Martin-Bastida and colleagues [222] reported removal of excess iron concentrations in the dentate and caudate nucleus, but minimal symptomatic improvement in PD patients, noting that the trial had small numbers of patients, was limited to early PD, and was only of six months’ duration. However, deferiprone is only bidentate and a relatively weak chelator
[128], and its combination with the stronger, tridentate deferasirox may prove more effective. Iron chelation may have some mild side-effects. However, deferiprone therapy was well tolerated by PD subjects with only minor side effects including exacerbation of pre-existing muscular/and joint pain or mild gastrointestinal upset [222].

The marginal success of simple metal chelation drugs like deferiprone is also possibly due to the multi-factorial aetiology of PD, and the various pathological feedback loops involved in disease pathology. Simply removing one feature of the disease would do little to stop its progression, or reverse its debilitating effects. Multifunctional agents, capable of targeting several underlying pathological mechanisms, have been in development for almost two decades [215, 224]. Compounds like piperaxine-8-OH-quinolone hybrids have been shown to have free radical scavenging properties, independent of their iron chelation function [225]. Multifunctional iron chelators, like 7,8-dihydroxycoumarin derivative (DHC12) and Coumarin-tris hybrid (CT51), have been designed to accumulate in the mitochondria, where both iron and ROS exist in high concentration, thereby increasing their antioxidant and mitochondriotropic effects [226, 227]. These agents are, however, still in the experimental phase and are yet to be proven effective during clinical trials. Ergothioneine is another promising iron chelator that is also an antioxidant [228].

5.3. Faecal microbiota transplantation

As mentioned previously, faecal transplantation of gut microbiota from PD patients enhanced α-Syn-mediated motor dysfunction in a mouse model of PD [107]. The question that now arises is whether the opposite might be true: can faecal transplants form a healthy individual assist in the treatment of PD patients? Indeed this seems to be the case, as faecal microbiota transplantation in PD is being investigated [229]. Faecal transplantation may be important to assist in recolonizing the gut microbiome of patients with neurodegenerative diseases [230]. There has been reports of case studies where faecal transplant were used in PD [231]. Faecal microbiota transplantation was also shown to protect mice in a PD model by suppressing neuroinflammation and reducing toll-like receptor (TLR)4/TNF-α signalling [232]. Once again, to fully understand the usefulness of this method and to present convincing clinical results, controlled clinical trials are needed.

5.4. Additional therapeutic options

Therapeutic interventions that directly target both LPS and gingipains could also be additional therapeutic options. Examples of such options may include small molecule inhibitors of gingipains [189]. An interesting option is the adjunctive use of lozenges containing IgY antibody against gingipains from P. gingivalis. It was shown that the use of this therapy resulted in clinical and microbiological benefits in the treatment for chronic periodontitis [233], and may actually also have therapeutic effects in PD.

6. Conclusion

In this review we have brought together evidence that the development and presence of PD depends on specific sets of interlinking factors that include neuro-inflammation, systemic inflammation, α-Syn-induced cell damage and vascular dysfunction, iron dysregulation, together with gut and periodontal dysbiosis. Published evidence substantiates the view that PD is both associated with and driven by dysregulated circulating inflammagens, iron and cytokines. In addition, bacterial inflammagens such as LPSs, and proteases such as gingipains, may also fuel inflammation, and might be central to the development of PD. Bacterial inflammagens may either enter via the gut or as a dual-hit mechanism, involving anterograde progression of pathology from the olfactory system into the temporal lobe, and retrograde progression to the brainstem [13, 14], and these processes may provide areas for therapeutic intervention. There is also evidence that pre-and probiotics, as well as antibiotics and faecal transplant treatment, might be valuable treatments in PD. A current challenge for drug discovery designed for complex brain disorders such as PD is to look for multimodal drugs with a disease-modifying effect [234]. Targeting underlying mechanisms of
PD, such as gut dysbiosis and iron toxicity, have elucidated a wide variety of novel treatments which could not only relieve the characteristic motor deficits seen in PD but might significantly slow the progression of the disease. We suggest that the most effective approach to prevent PD and its worsening is to determine the origin of the disease and its comorbidities and to follow a personalized treatment regime, of which we outline the main features. Most treatment options discussed here may be most effective against the comorbidities that are related to non-motor symptoms; such symptoms may mostly precede motor symptoms. In such a personalized treatment approach, all multifactorial features should be explored. Ultimately, we need to embark on long-term longitudinal studies where large cohort data are available.

**Author Contributions:** Conceptualization, E.P., D.B.K. and J.A.C.; writing—original draft preparation, M.J.V.V. and T.A.N.; writing—review and editing, E.P., D.B.K., J.A.C, T.A.N. and M.J.V.V. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Medical Research Council of South Africa (MRC), grant number: A0X331 Self-initiated research and The Novo Nordisk Foundation, grant number: NNF10CC1016517.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| α-Syn | Alpha-synuclein |
| AD | Alzheimer's disease |
| Aβ | Beta-amyloid |
| BBB | Blood brain barrier |
| CD | Cluster of differentiation 14 |
| CNS | Central nervous system |
| COX-2 | Cyclooxygenase-2 |
| CRP | C-reactive protein |
| CT51 | Coumarin-tris hybrid |
| DHC12 | 7,8-dihydroxycoumarin-12 |
| Hgb | Haemoglobin |
| IFNγ | Interferon-gamma |
| IL | Interleukin |
| iNOS | Inducible nitric oxide synthase |
| LB | Lewy body |
| LPS | Lipopolysaccharide |
| LTA | Lipoteichoic acid |
| MRC | Medical Research Council of South Africa |
| mRNA | Messenger ribonucleic acid |
| MOA | Monoamine oxidase |
| NADPH | Nicotinamide adenine dinucleotide phosphate reduced |
| NF-κB | Nuclear Factor kappa-light-chain-enhancer of activated B cells |
| PARK | Parkinson's disease genes |
| PD | Parkinson's disease |
| RANTES | Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted |
| REM | Rapid eye movement |
| Rgp | Gingipain |
| ROS | Reactive oxygen species |
| SAA | Serum amyloid A |
| SNc | Substantia nigra pars compacta |
| SUMO | Small ubiquitin-like modifier |
 TEM  Transmission electron microscope  
 TLR  Toll-like receptor  
 TNF-α  Tumor necrosis factor-alpha  
 TFN  Transferrin

References
1. Dorsey, E. R.; Elbaz, A.; Nichols, E.; Abd-Allah, F.; Abdelalim, A.; Adsuar, J. C.; Ansha, M. G.; Brayne, C.; Choi, J.-Y. J.; Collado-Mateo, D., Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology 2018, 17, (11), 939-953.
2. Bach, J. P.; Ziegler, U.; Deuschl, G.; Dodel, R.; Dobhammer-Reiter, G., Projected numbers of people with movement disorders in the years 2030 and 2050. Movement disorders 2011, 26, (12), 2286-2290.
3. Dorsey, E. R.; Bloem, B. R., The Parkinson pandemic—a call to action. Jama neurology 2018, 75, (1), 9-10.
4. Bhattacharjee, P.; Öhrfelt, A.; Lashley, T.; Blennow, K.; Brinkmalm, A.; Zetterberg, H., Mass Spectrometric Analysis of Lewy Body-Enriched α-Synuclein in Parkinson’s Disease. J Proteome Res 2019, 18, (5), 2109-2120.
5. Del Tredici, K.; Rüb, U.; De Vos, R. A.; Bohl, J. R.; Braak, H., Where does Parkinson disease pathology begin in the brain? Journal of Neuropathology & Experimental Neurology 2002, 61, (5), 413-426.
6. Braak, H.; Del Tredici, K.; Rub, U.; de Vos, R. A.; Jansen Steur, E. N.; Braak, E., Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003, 24, (2), 197-211.
7. Braak, H.; Rüb, U.; Gai, W.; Del Tredici, K., Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of neural transmission 2003, 110, (5), 517-536.
8. Farrand, A. Q.; Helke, K. L.; Gregory, R. A.; Gooz, M.; Hinson, V. K.; Boger, H. A., Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson’s disease. Brain Stimul 2017, 10, (6), 1045-1054.
9. Devos, D.; Lebouvier, T.; Lardeux, B.; Biraud, M.; Rouaud, T.; Pouclet, H.; Coron, E.; Bruley des Varannes, S.; Naveilhan, P.; Nguyen, J. M.; Neunlist, M.; Derkinderen, P., Colonic inflammation in Parkinson’s disease. Neurobiology of disease 2013, 50, 42-8.
10. Grunevald, A.; Kumar, K. R.; Sue, C. M., New insights into the complex role of mitochondria in Parkinson’s disease. Prog Neurobiol 2019, 177, 73-93.
11. Jucker, M.; Walker, L. C., Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013, 501, (7465), 45-51.
12. Volpicelli-Daley, L. A.; Luk, K. C.; Patel, T. P.; Tanik, S. A.; Riddle, D. M.; Stieber, A.; Meaney, D. F.; Trojanowski, J. Q.; Lee, V. M., Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011, 72, (1), 57-71.
13. Hawkes, C. H.; Del Tredici, K.; Braak, H., Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007, 33, (6), 599-614.
14. Reichmann, H., View point: etiology in Parkinson’s disease. Dual hit or spreading intoxication. J Neurol Sci 2011, 310, (1-2), 9-11.
15. Shannon, K. M.; Keshavarzian, A.; Mutlu, E.; Dodiya, H. B.; Daian, D.; Jaglin, J. A.; Kordower, J. H., Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease. *Mov Disord* 2012, 27, (6), 709-15.

16. Wynford-Thomas, R.; Robertson, N. P., The role of skin biopsy in differentiating idiopathic Parkinson’s disease from other types of parkinsonism. *J Neurol* 2015, 262, (12), 2793-5.

17. Claassen, D. O.; Josephs, K. A.; Ahlskog, J. E.; Silber, M. H.; Tippmann-Peikert, M.; Boeve, B. F., REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. *Neurology* 2010, 75, (6), 494-9.

18. Abbott, R. D.; Petrovitch, H.; White, L. R.; Masaki, K. H.; Tanner, C. M.; Curb, J. D.; Grandinetti, A.; Blanchette, P. L.; Popper, J. S.; Ross, G. W., Frequency of bowel movements and the future risk of Parkinson’s disease. *Neurology* 2001, 57, (3), 456-62.

19. Nuzum, N. D.; Loughman, A.; Szymlek-Gay, E. A.; Hendy, A.; Teo, W. P.; Macpherson, H., Gut microbiota differences between healthy older adults and individuals with Parkinson’s disease: A systematic review. *Neurosci Biobehav Rev* 2020, 112, 227-241.

20. Funke, C.; Schneider, S. A.; Berg, D.; Kell, D. B., Genetics and iron in the systems biology of Parkinson’s disease and some related disorders. *Neurochemistry international* 2013, 62, (5), 637-52.

21. Klein, C.; Westenberger, A., Genetics of Parkinson’s disease. *Cold Spring Harbor perspectives in medicine* 2012, 2, (1), a008888.

22. Genoud, S.; Senior, A. M.; Hare, D. J.; Double, K. L., Meta-Analysis of Copper and Iron in Parkinson’s Disease Brain and Biofluids. *Mov Disord* 2020, 35, (4), 662-671.

23. Bhattacharyya, D.; Mohite, G. M.; Krishnamoorthy, J.; Gayen, N.; Mehra, S.; Navalkar, A.; Kotler, S. A.; Rath, B. N.; Ghosh, A.; Kumar, R., Lipopolysaccharide from Gut Microbiota Modulates α-Synuclein Aggregation and Alters Its Biological Function. *ACS chemical neuroscience* 2019, 10, (5), 2229-2236.

24. Calabrese, V.; Santoro, A.; Monti, D.; Crupi, R.; Di Paola, R.; Latteri, S.; Cuzzocrea, S.; Zappia, M.; Giordano, J.; Calabrese, E. J., Aging and Parkinson’s Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis. *Free Radical Biology and Medicine* 2018, 115, 80-91.

25. Caputi, V.; Giron, M. C., Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease. *Int J Mol Sci* 2018, 19, (6).

26. Mukherjee, A.; Biswas, A.; Das, S. K., Gut dysfunction in Parkinson’s disease. *World J Gastroenterol* 2016, 22, (25), 5742-52.

27. Müller, T.; Palluch, R.; Jackowski, J., Caries and periodontal disease in patients with Parkinson’s disease. *Spec Care Dentist* 2011, 31, (5), 178-81.

28. Parashar, A.; Udayabanu, M., Gut microbiota: Implications in Parkinson’s disease. *Parkinsonism Relat Disord* 2017, 38, 1-7.

29. De Virgilio, A.; Greco, A.; Fabbrini, G.; Inghilleri, M.; Rizzo, M. I.; Gallo, A.; Conte, M.; Rosato, C.; Ciniglio Appiani, M.; de Vincentiis, M., Parkinson’s disease: Autoimmunity and neuroinflammation. *Autoimmun Rev* 2016, 15, (10), 1005-11.

30. Grozdanov, V.; Bousset, L.; Hoffmeister, M.; Bliederhaeuser, C.; Meier, C.; Madiona, K.; Pieri, L.; Kiechle, M.; McLean, P. J.; Kassubek, J.; Behrends, C.; Ludolph, A. C.; Weishaupt, J. H.; Melki, R.; Danzer, K. M., Increased Immune Activation by Pathologic α-Synuclein in Parkinson’s Disease. *Ann Neurol* 2019, 86, (4), 593-606.
31. Butkovich, L. M.; Houser, M. C.; Tansey, M. G., α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson’s Disease Pathogenesis. *Front Neurosci* 2018, 12, 626.

32. Kannarkat, G. T.; Boss, J. M.; Tansey, M. G., The role of innate and adaptive immunity in Parkinson’s disease. *Journal of Parkinson’s disease* 2013, 3 (4), 493-514.

33. Kim, R.; Kim, H. J.; Kim, A.; Jang, M.; Kim, A.; Kim, Y.; Yoo, D.; Im, J. H.; Choi, J. H.; Jeon, B., Peripheral blood inflammatory markers in early Parkinson’s disease. *J Clin Neurosci* 2018, 58, 30-33.

34. Williams-Gray, C. H.; Wijeyekoon, R.; Yarnall, A. J.; Lawson, R. A.; Breen, D. P.; Evans, J. R.; Cummins, G. A.; Duncan, G. W.; Khoo, T. K.; Burn, D. J.; Barker, R. A., Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD). *Mov Disord* 2016, 31, (7), 995-1003.

35. Eidson, L. N.; Kannarkat, G. T.; Barnum, C. J.; Chang, J.; Chung, J.; Caspell-Garcia, C.; Taylor, P.; Mollenhauer, B.; Schlossmacher, M. G.; Ereshefsky, L.; Yen, M.; Kopil, C.; Frasier, M.; Marek, K.; Hertzberg, V. S.; Tansey, M. G., Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease. *J Neuroinflammation* 2017, 14, (1), 164.

36. McGeer, P. L.; McGeer, E. G., Inflammation and neurodegeneration in Parkinson’s disease. *Parkinsonism Relat Disord* 2004, 10 Suppl 1, S3-7.

37. Perry, V. H., Innate inflammation in Parkinson’s disease. *Cold Spring Harbor perspectives in medicine* 2012, 2, (9), a009373.

38. Stojkovska, I.; Wagner, B. M.; Morrison, B. E., Parkinson’s disease and enhanced inflammatory response. *Exp Biol Med (Maywood)* 2015, 240, (11), 1387-95.

39. Caggiu, E.; Arru, G.; Hosseini, S.; Niegowska, M.; Sechi, G.; Zarbo, I. R.; Sechi, L. A., Inflammation, Infectious Triggers, and Parkinson’s Disease. *Front Neurol* 2019, 10, 122.

40. Tansey, M. G.; Romero-Ramos, M., Immune system responses in Parkinson’s disease: Early and dynamic. *Eur J Neurosci* 2019, 49, (3), 364-383.

41. Benakis, C.; Martin-Gallausiaux, C.; Trezzi, J. P.; Melton, P.; Liesz, A.; Wilmes, P., The microbiome-gut-brain axis in acute and chronic brain diseases. *Curr Opin Neuropathol* 2020, 61, 1-9.

42. Mulak, A.; Bonaz, B., Brain-gut-microbiota axis in Parkinson’s disease. *World J Gastroenterol* 2015, 21, (37), 10609-20.

43. Nair, A. T.; Ramachandran, V.; Joghee, N. M.; Antony, S.; Ramalingam, G., Gut Microbiota Dysfunction as Reliable Non-invasive Early Diagnostic Biomarkers in the Pathophysiology of Parkinson’s Disease: A Critical Review. *J Neurogastroenterol Motil* 2018, 24, (1), 30-42.

44. Kell, D. B.; Pretorius, E., No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases. *Biological Reviews* 2018, 93, (3), 1518-1557.

45. Adams, B.; Nunes, J. M.; Page, M. J.; Roberts, T.; Carr, J.; Nell, T. A.; Kell, D. B.; Pretorius, E., Parkinson’s Disease: A Systemic Inflammatory Disease Accompanied by Bacterial Inflammagens. *Front Aging Neurosci* 2019, 11, 210.

46. Pessoa Rocha, N.; Reis, H. J.; Vanden Berghe, P.; Cirillo, C., Depression and cognitive impairment in Parkinson’s disease: a role for inflammation and immunomodulation? *Neuroimmunomodulation* 2014, 21, (2-3), 88-94.

47. Deleidi, M.; Gasser, T., The role of inflammation in sporadic and familial Parkinson’s disease. *Cellular and molecular life sciences : CMLS* 2013, 70, (22), 4259-73.
48. More, S. V.; Kumar, H.; Kim, I. S.; Song, S. Y.; Choi, D. K., Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson’s disease. *Mediators of inflammation* 2013, 2013, 952375.
49. Nolan, Y. M.; Sullivan, A. M.; Toulouse, A., Parkinson’s disease in the nuclear age of neuroinflammation. *Trends in molecular medicine* 2013, 19, (3), 187-96.
50. Taylor, J. M.; Main, B. S.; Crack, P. J., Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson’s disease. *Neurochemistry international* 2013, 62, (5), 803-19.
51. Filiou, M. D.; Arefin, A. S.; Moscato, P.; Graeber, M. B., ‘Neuroinflammation’ differs categorically from inflammation: transcriptomes of Alzheimer’s disease, Parkinson’s disease, schizophrenia and inflammatory diseases compared. *Neurogenetics* 2014, 15, (3), 201-12.
52. Perez, A.; Guan, L.; Sutherland, K.; Cao, C., Immune system and Parkinson’s disease. *Arch Med 2016*, 8, (2), 1-6.
53. Jiang, H.; Wang, J.; Rogers, J.; Xie, J., Brain Iron Metabolism Dysfunction in Parkinson’s Disease. *Mol Neurobiol 2017*, 54, (4), 3078-3101.
54. Berg, D.; Youdim, M. B., Role of iron in neurodegenerative disorders. *Top Magn Reson Imaging 2006*, 17, (1), 5-17.
55. Altmura, S.; Muckenthaler, M. U., Iron toxicity in diseases of aging: Alzheimer’s disease, Parkinson’s disease and atherosclerosis. *Journal of Alzheimer’s disease : JAD 2009*, 16, (4), 879-95.
56. Kell, D. B., Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. *BMC medical genomics 2009*, 2, 2.
57. Schneider, S. A.; Hardy, J.; Bhatia, K. P., Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. *Mov Disord 2012*, 27, (1), 42-53.
58. Hare, D. J.; Double, K. L., Iron and dopamine: a toxic couple. *Brain 2016*, 139, (Pt 4), 1026-35.
59. Knorle, R., Neuromelanin in Parkinson’s Disease: from Fenton Reaction to Calcium Signaling. *Neurotox Res 2018*, 33, (2), 515-522.
60. Pretorius, E.; Swanepoel, A. C.; Buys, A. V.; Vermeulen, N.; Duim, W.; Kell, D. B., Eryptosis as a marker of Parkinson’s disease. *Aging (Albany NY) 2014*, 6, (10), 788.
61. Stojakovic, A.; Paz-Filho, G.; Arcos-Burgos, M.; Licinio, J.; Wong, M. L.; Mastronardi, C. A., Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement. *Mol Neurobiol 2017*, 54, (6), 4486-4495.
62. Alam, Q.; Alam, M. Z.; Mushtaq, G.; Damanhour, G. A.; Rasool, M.; Kamal, M. A.; Haque, A., Inflammatory Process in Alzheimer’s and Parkinson’s Diseases: Central Role of Cytokines. *Curr Pharm Des 2016*, 22, (5), 541-8.
63. Sanchez-Guajardo, V.; Tentillier, N.; Romero-Ramos, M., The relation between α-synuclein and microglia in Parkinson’s disease: Recent developments. *Neuroscience 2015*, 302, 47-58.
64. Joers, V.; Tansey, M. G.; Mulas, G.; Carta, A. R., Microglial phenotypes in Parkinson’s disease and animal models of the disease. *Prog Neurobiol 2017*, 155, 57-75.
65. Olanow, C. W., The pathogenesis of cell death in Parkinson’s disease--2007. *Mov Disord 2007*, 22 Suppl 17, (S17), S335-42.
66. Andersen, J. K., Oxidative stress in neurodegeneration: cause or consequence? *Nat Med 2004*, 10 Suppl, (7s), S18-25.
67. Sanchez-Guajardo, V.; Barnum, C. J.; Tansey, M. G.; Romero-Ramos, M., Neuroimmunological processes in Parkinson’s disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. *ASN neuro* 2013, 5, (2), AN20120066.

68. Castro, A.; Macedo-de la Concha, L.; Pantoja-Meléndez, C., Low-grade inflammation and its relation to obesity and chronic degenerative diseases. *Revista Médica del Hospital General de México* 2017, 80, (2), 101-105.

69. Barcia, C.; Ros, C. M.; Annes, V.; Gomez, A.; Ros-Bernal, F.; Aguado-Yera, D.; Martinez-Pagan, M. E.; de Pablos, V.; Fernandez-Villalba, E.; Herrero, M. T., IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson’s disease. *Cell Death Dis* 2011, 2, (4), e142.

70. Boka, G.; Anglade, P.; Wallach, D.; Javoy-Agid, F.; Agid, Y.; Hirsch, E. C., Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. *Neurosci Lett* 1994, 172, (1-2), 151-4.

71. Depino, A. M.; Earl, C.; Kaczmarczyk, E.; Ferrari, C.; Besedovsky, H.; del Rey, A.; Pitossi, F. J.; Oertel, W. H., Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson’s disease. *Eur J Neurosci* 2003, 18, (10), 2731-42.

72. Song, I.-U.; Chung, S.-W.; Kim, J.-S.; Lee, K.-S., Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson’s disease. *Neurological Sciences* 2011, 32, (1), 31-34.

73. Rathnayake, D.; Chang, T.; Udagama, P., Selected serum cytokines and nitric oxide as potential multi-marker biosignature panels for Parkinson disease of varying durations: a case-control study. *BMC neurology* 2019, 19, (1), 56.

74. Qin, X. Y.; Zhang, S. P.; Cao, C.; Loh, Y. P.; Cheng, Y., Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis. *JAMA Neurol* 2016, 73, (11), 1316-1324.

75. Fiszer, U.; Mix, E.; Fredrikson, S.; Kostulas, V.; Olsson, T.; Link, H., γδ+ T cells are increased in patients with Parkinson’s disease. *Journal of the neurological sciences* 1994, 121, (1), 39-45.

76. Bas, J.; Calopa, M.; Mestre, M.; Mollevi, D. G.; Cutillas, B.; Ambrosio, S.; Buendia, E., Lymphocyte populations in Parkinson’s disease and in rat models of parkinsonism. *J Neuroimmunol* 2001, 113, (1), 146-52.

77. Hunot, S.; Boissiere, F.; Faucheux, B.; Brugg, B.; Mouatt-Prigent, A.; Agid, Y.; Hirsch, E., Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. *Neuroscience* 1996, 72, (2), 355-363.

78. Knott, C.; Stern, G.; Wilkin, G., Inflammatory regulators in Parkinson’s disease: iNOS, lipocortin-1, and cyclooxygenases-1 and-2. *Molecular and Cellular Neuroscience* 2000, 16, (6), 724-739.

79. Houser, M. C.; Tansey, M. G., The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? *NPJ Parkinsons Dis* 2017, 3, 3.

80. Perez-Pardo, P.; Hartog, M.; Garssen, J.; Kraneveld, A. D., Microbes Tickling Your Tummy: the Importance of the Gut-Brain Axis in Parkinson’s Disease. *Curr Behav Neurosci Rep* 2017, 4, (4), 361-368.

81. Houser, M. C.; Chang, J.; Factor, S. A.; Molho, E. S.; Zabetian, C. P.; Hill-Burns, E. M.; Payami, H.; Hertzberg, V. S.; Tansey, M. G., Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson’s Disease. *Mov Disord* 2018, 33, (5), 793-804.
82. Schwierz, A.; Spiegel, J.; Dillmann, U.; Grundmann, D.; Bürmann, J.; Faßbender, K.; Schäfer, K. H.; Unger, M. M., Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson’s disease. *Parkinsonism Relat Disord* 2018, 50, 104-107.

83. de Waal, G. M.; Engellbrecht, L.; Davis, T.; de Villiers, W. J.; Kell, D. B.; Pretorius, E., Correlative Light-Electron Microscopy detects lipopolysaccharide and its association with fibrin fibres in Parkinson’s Disease, Alzheimer’s Disease and Type 2 Diabetes Mellitus. *Scientific reports* 2018, 8, (1), 16798.

84. Hasegawa, S.; Goto, S.; Tsuji, H.; Asahara, T.; Nomoto, K.; Shibata, A.; Fujisawa, Y.; Minato, T.; Okamoto, A.; Ohno, K.; Hirayama, M., Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson’s Disease. *PloS one* 2015, 10, (11), e0142164.

85. Wijeyekoon, R. S.; Kronenberg-Versteeg, D.; Scott, K. M.; Hayat, S.; Kuan, W. L.; Evans, J. R.; Breen, D. P.; Cummins, G.; Jones, J. L.; Clatworthy, M. R.; Floto, R. A.; Barker, R. A.; Williams-Gray, C. H., Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson’s disease. *Brain Behav Immun* 2020, 87, 473-488.

86. Barnham, K. J.; Bush, A. I., Metals in Alzheimer’s and Parkinson’s diseases. *Current opinion in chemical biology* 2008, 12, (2), 222-8.

87. Bartzokis, G.; Tishler, T. A.; Lu, P. H.; Villablanca, P.; Altshuler, L. L.; Carter, M.; Huang, D.; Edwards, N.; Mintz, J., Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. *Neurobiol Aging* 2007, 28, (3), 414-23.

88. Berg, D.; Hochstrasser, H., Iron metabolism in Parkinsonian syndromes. *Mov Disord* 2006, 21, (9), 1299-310.

89. Boelmans, K.; Holst, B.; Hackius, M.; Finsterbusch, J.; Gerloff, C.; Fiehler, J.; Munchau, A., Brain iron deposition fingerprints in Parkinson’s disease and progressive supranuclear palsy. *Mov Disord* 2012, 27, (3), 421-7.

90. Gotz, M. E.; Double, K.; Gerlach, M.; Youdim, M. B.; Riederer, P., The relevance of iron in the pathogenesis of Parkinson’s disease. *Annals of the New York Academy of Sciences* 2004, 1012, 193-208.

91. Genoud, S.; Vondrakova, D.; Lawson, M.; Valko, M., Metals, oxidative stress and neurodegenerative disorders. *Molecular and cellular biochemistry* 2010, 345, (1-2), 91-104.

92. Lewis, M. M.; Du, G.; Kidacki, M.; Patel, N.; Shaffer, M. L.; Mailman, R. B.; Huang, X., Higher iron in the red nucleus marks Parkinson’s dyskinesia. *Neurobiol Aging* 2013, 34, (5), 1497-503.

93. Lingor, P.; Carboni, E.; Koch, J. C., Alpha-synuclein and iron: two keys unlocking Parkinson’s disease. *J Neural Transm (Vienna)* 2017, 124, (8), 973-981.

94. Logroscino, G.; Marder, K.; Graziano, J.; Freyer, G.; Slavkovich, V.; Lolacono, N.; Cote, L.; Mayeux, R., Altered systemic iron metabolism in Parkinson’s disease. *Neurology* 1997, 49, (3), 714-7.

95. Thomas, M.; Jankovic, J., Neurodegenerative disease and iron storage in the brain. *Current opinion in neurology* 2004, 17, (4), 437-42.

96. Genoud, S.; Roberts, B. R.; Gunn, A. P.; Halliday, G. M.; Lewis, S. J. G.; Ball, H. J.; Hare, D. J.; Double, K. L., Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson’s disease brain. *Metallomics* 2017, 9, (10), 1447-1455.

97. Sampson, T. R.; Challis, C.; Jain, N.; Moiseyenko, A.; Ladinsky, M. S.; Shastri, G. G.; Thron, T.; Needham, B. D.; Horvath, I.; Debelius, J. W.; Janssen, S.; Knight, R.; Wittung-Stafshede, P.; Gradinaru, V.; Chapman, M.; Mazmanian, S. K., A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice. *Elife* 2020, 9.
98. Borghammer, P.; Van Den Berge, N., Brain-First versus Gut-First Parkinson's Disease: A Hypothesis. *Journal of Parkinson's disease* 2019, 9, (s2), S281-s295.

99. Asahina, M.; Vichayanrat, E.; Low, D. A.; Iodice, V.; Mathias, C. J., Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology. *J Neural Neurosurg Psychiatry* 2013, 84, (6), 674-80.

100. Merola, A.; Coon, E. A., Dysautonomia in early Parkinson disease: a window into the determinants of functional disability and an opportunity for early intervention. *Clinical Autonomic Research: Official Journal of the Clinical Autonomic Research Society* 2020.

101. Anang, J. B.; Gagnon, J. F.; Bertrand, J. A.; Romenets, S. R.; Latreille, V.; Panisset, M.; Montplaisir, J.; Postuma, R. B., Predictors of dementia in Parkinson disease: a prospective cohort study. *Neurology* 2014, 83, (14), 1253-60.

102. Mendoza-Velasquez, J. J.; Flores-Vazquez, J. F.; Barron-Velazquez, E.; Sosa-Ortiz, A. L.; Illigens, B. W.; Siepmann, T., Autonomic Dysfunction in alpha-Synucleinopathies. *Front Neurol* 2019, 10, 363.

103. Sharma, A.; Kurek, J.; Morgan, J. C.; Wakade, C.; Rao, S. S. C., Constipation in Parkinson’s Disease: a Nuisance or Nuanced Answer to the Pathophysiological Puzzle? *Curr Gastroenterol Rep* 2018, 20, (1), 1.

104. Hilton, D.; Stephens, M.; Kirk, L.; Edwards, P.; Potter, R.; Zajicek, J.; Broughton, E.; Hagan, H.; Carroll, C., Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease. *Acta Neuropathol* 2014, 127, (2), 235-41.

105. Corbillé, A. G.; Preterre, C.; Rolli-Derkinderen, M.; Coron, E.; Neunlist, M.; Lebouvier, T.; Derkinderen, P., Biochemical analysis of α-synuclein extracted from control and Parkinson’s disease colonic biopsies. *Neurosci Lett* 2017, 641, 81-86.

106. Kaufmann, H.; Norcliffe-Kaufmann, L.; Palma, J. A.; Biaggioni, I.; Low, P. A.; Singer, W.; Goldstein, D. S.; Peltier, A. C.; Shibao, C. A.; Gibbons, C. H.; Freeman, R.; Robertson, D.; Autonomic Disorders, C., Natural history of pure autonomic failure: A United States prospective cohort. *Ann Neurol* 2017, 81, (2), 287-297.

107. Sampson, T. R.; Debelius, J. W.; Thron, T.; Janssen, S.; Shastry, G. G.; Ilhan, Z. E.; Challis, C.; Schretter, C. E.; Rocha, S.; Gradinaru, V.; Chesselet, M. F.; Keshavarzian, A.; Shannon, K. M.; Krajmalnik-Brown, R.; Wittung-Stafshede, P.; Knight, R.; Mazmanian, S. K., Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease. *Cell* 2016, 167, (6), 1469-1480 e12.

108. Bonaz, B.; Bazin, T.; Pellissier, S., The vagus nerve at the interface of the microbiota-gut-brain axis. *Frontiers in neuroscience* 2018, 12, 49.

109. Ueki, A.; Otsuka, M., Life style risks of Parkinson’s disease: association between decreased water intake and constipation. *Journal of neurology* 2004, 251, (7), vii18-vii23.

110. Braak, H.; de Vos, R. A.; Bohl, J.; Del Tredici, K., Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. *Neurosci Lett* 2006, 396, (1), 67-72.

111. Verbaan, D.; Marinus, J.; Visser, M.; van Roojen, S. M.; Stiggelbout, A. M.; van Hilten, J. J., Patient-reported autonomic symptoms in Parkinson disease. *Neurology* 2007, 69, (4), 333-41.

112. Scheperjans, F.; Aho, V.; Pereira, P. A.; Koskinen, K.; Paulin, L.; Pekkonen, E.; Haapaniemi, E.; Kaakkola, S.; Eerola-Rautio, J.; Pohja, M.; Kinnunen, E.; Murros, K.; Auvinen, P., Gut microbiota are related to Parkinson’s disease and clinical phenotype. *Mov Disord* 2015, 30, (3), 350-8.
113. Keshavarzian, A.; Green, S. J.; Engen, P. A.; Voigt, R. M.; Naqib, A.; Forsyth, C. B.; Mutlu, E.; Shannon, K. M., Colonic bacterial composition in Parkinson’s disease. *Mov Disord* 2015, 30, (10), 1351-60.

114. Cersosimo, M. G.; Benarroch, E. E., Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. *Mov Disord* 2012, 46, (3), 559-64.

115. Forsyth, C. B.; Shannon, K. M.; Kordower, J. H.; Voigt, R. M.; Shaikh, M.; Jaglin, J. A.; Estes, J. D.; Dodiya, H. B.; Keshavarzian, A., Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. *PloS one* 2011, 6, (12), e28032.

116. Shannon, K. M.; Keshavarzian, A.; Dodiya, H. B.; Jakate, S.; Kordower, J. H., Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases. *Mov Disord* 2012, 27, (6), 716-9.

117. Holmqvist, S.; Chutna, O.; Bousset, L.; Aldrin-Kirk, P.; Li, W.; Bjorklund, T.; Wang, Z. Y.; Roybon, L.; Melki, R.; Li, J. Y., Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. *Acta Neuropathol* 2014, 128, (6), 805-20.

118. Svensson, E.; Horvath-Puho, E.; Thomsen, R. W.; Djurhuus, J. C.; Pedersen, L.; Borghammer, P.; Sorensen, H. T., Vagotomy and subsequent risk of Parkinson’s disease. *Ann Neurol* 2015, 78, (4), 522-9.

119. Clarke, G.; Grenham, S.; Scully, P.; Fitzgerald, P.; Moloney, R. D.; Shanahan, F.; Dinan, T. G.; Cryan, J. F., The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. *Mol Psychiatry* 2013, 18, (6), 666-73.

120. Van Den Berge, N.; Ferreira, N.; Gram, H.; Mikkelsen, T. W.; Alstrup, A. K. O.; Casadei, N.; Tsung-Pin, P.; Riess, O.; Nyengaard, J. R.; Tamgüney, G.; Jensen, P. H.; Borghammer, P., Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. *Acta Neuropathol* 2019, 138, (4), 535-550.

121. Manfredsson, F. P.; Luk, K. C.; Benskey, M. J.; Gezer, A.; Garcia, J.; Kuhn, N. C.; Sandoval, I. M.; Patterson, J. R.; O’Mara, A.; Yonkers, R.; Kordower, J. H., Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. *Neurobiology of disease* 2018, 112, 106-118.

122. Challis, C.; Hori, A.; Sampson, T. R.; Yoo, B. B.; Challis, R. C.; Hamilton, A. M.; Mazmanian, S. K.; Volpicelli-Daley, L. A.; Gradinaru, V., Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. *Nat Neurosci* 2020, 23, (3), 327-336.

123. Breen, D. P.; Halliday, G. M.; Lang, A. E., Gut-brain axis and the spread of α-synuclein pathology: Vagal highway or dead end? *Mov Disord* 2019, 34, (3), 307-316.

124. Kim, Y.-J.; Chung, W. C.; Kim, B. W.; Kim, S. S.; Kim, J. I.; Kim, N. J.; Yoo, J.; Kim, S. H., Is Helicobacter pylori associated functional dyspepsia correlated with dysbiosis? *Journal of neurogastroenterology and motility* 2017, 23, (4), 504.

125. Choi, V. M.; Herrou, J.; Hecht, A. L.; Teoh, W. P.; Turner, J. R.; Crosson, S.; Bubeck Wardenburg, J., Activation of Bacteroides fragilis toxin by a novel bacterial protease contributes to anaerobic sepsis in mice. *Nat Med* 2016, 22, (5), 563-7.

126. Seong, K.-J.; Lee, H.-G.; Kook, M. S.; Ko, H.-M.; Jung, J.-Y.; Kim, W.-J., Epigallocatechin-3-gallate rescues LPS-impaired adult hippocampal neurogenesis through suppressing the TLR4-NF-κB signaling pathway in mice. *The Korean Journal of Physiology & Pharmacology* 2016, 20, (1), 41-51.
127. Pretorius, L.; Kell, D. B.; Pretorius, E., Iron Dysregulation and Dormant Microbes as Causative Agents for Impaired Blood Rheology and Pathological Clotting in Alzheimer’s Type Dementia. *Frontiers in neuroscience* 2018, 12, 851.

128. Kell, D. B.; Pretorius, E., Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. *Progress in biophysics and molecular biology* 2017, 123, 16-41.

129. Furuta, N.; Takeuchi, H.; Amano, A., Entry of Porphyromonas gingivalis outer membrane vesicles into epithelial cells causes cellular functional impairment. *Infection and immunity* 2009, 77, (11), 4761-4770.

130. Poole, S.; Singhrao, S. K.; Kesavalu, L.; Curtis, M. A.; Crean, S., Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer’s disease brain tissue. *Journal of Alzheimer’s disease: JAD* 2013, 36, (4), 665-77.

131. Del Prete, S.; De Luca, V.; Scozzafava, A.; Carginale, V.; Supuran, C. T.; Capasso, C., Biochemical properties of a new alpha-carbonic anhydrase from the human pathogenic bacterium, Vibrio cholerae. *J Enzyme Inhib Med Chem* 2014, 29, (1), 23-7.

132. Bielecka, E.; Scavenius, C.; Kántyka, T.; Jusko, M.; Mizgalska, D.; Szmigielski, B.; Potempa, B.; Enghild, J. J.; Prossnitz, E. R.; Blom, A. M.; Potempa, J., Peptidyl arginine deiminase from Porphyromonas gingivalis abolishes anaphylatoxin C5a activity. *J Biol Chem* 2014, 289, (47), 32481-7.

133. Chen, S. G.; Stribinskis, V.; Rane, M. J.; Demuth, D. R.; Gozal, E.; Roberts, A. M.; Jagadapillai, R.; Liu, R.; Choe, K.; Shivakumar, B.; Son, F.; Jin, S.; Kerber, R.; Adame, A.; Masliah, E.; Friedland, R. P., Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans. *Sci Rep* 2016, 6, 34477.

134. Friedland, R. P.; Chapman, M. R., The role of microbial amyloid in neurodegeneration. *PLoS Pathog* 2017, 13, (12), e1006654.

135. Pretorius, E.; Bester, J.; Mbotwa, S.; Robinson, C.; Kell, D. B., Acute induction of anomalous blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide (LPS). *BioRxiv* 2016, 053538.

136. Holst, O., The structures of core regions from enterobacterial lipopolysaccharides–an update. *FEMS microbiology letters* 2007, 271, (1), 3-11.

137. Steimle, A.; Autenrieth, I. B.; Frick, J. S., Structure and function: Lipid A modifications in commensals and pathogens. *Int J Med Microbiol* 2016, 306, (5), 290-301.

138. Ege, M. J., The Hygiene Hypothesis in the Age of the Microbiome. *Ann Am Thorac Soc* 2017, 14, (Supplement 5), S348-s353.

139. Vatanen, T.; Kostic, A. D.; d’Hennezel, E.; Siljander, H.; Franzosa, E. A.; Yassour, M.; Kolde, R.; Vlamakis, H.; Arthur, T. D.; Hämäläinen, A. M.; Peet, A.; Tillmann, V.; Uibo, R.; Mokurov, S.; Dorshakova, N.; Ilonen, J.; Virtanen, S. M.; Szabo, S. J.; Porter, J. A.; Lähdesmäki, H.; Huttenhower, C.; Gevers, D.; Cullen, T. W.; Knip, M.; Xavier, R. J., Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. *Cell* 2016, 165, (6), 1551.

140. Perez-Pardo, P.; Dodiya, H. B.; Engen, P. A.; Forsyth, C. B.; Huschens, A. M.; Shaikh, M.; Voigt, R. M.; Naqib, A.; Green, S. J.; Kordower, J. H.; Shannon, K. M.; Garssen, J.; Kraneveld, A. D.; Keshavarzian, A., Role of TLR4 in the gut-brain axis in Parkinson’s disease: a translational study from men to mice. *Gut* 2019, 68, (5), 829-843.
141. Lu, Y. C.; Yeh, W. C.; Ohashi, P. S., LPS/TLR4 signal transduction pathway. *Cytokine* **2008**, *42*, (2), 145-151.

142. Park, B. S.; Lee, J. O., Recognition of lipopolysaccharide pattern by TLR4 complexes. *Exp Mol Med* **2013**, *45*, (12), e66.

143. Raetz, C. R.; Whitfield, C., Lipopolysaccharide endotoxins. *Annu Rev Biochem* **2002**, *71*, 635-700.

144. Pugin, J.; Schürer-Maly, C. C.; Leturcq, D.; Moriarty, A.; Ulevitch, R. J.; Tobias, P. S., Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. *Proc Natl Acad Sci U S A* **1993**, *90*, (7), 2744-8.

145. Chow, J. C.; Young, D. W.; Golenbock, D. T.; Christ, W. J.; Gusovsky, F., Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. *J Biol Chem* **1999**, *274*, (16), 10689-92.

146. Cohen, J., The immunopathogenesis of sepsis. *Nature* **2002**, *420*, (6917), 885-91.

147. Man, S. M.; Kanneganti, T. D., Regulation of inflammasome activation. *Immunol Rev* **2015**, *265*, (1), 6-21.

148. Gao, H.-M.; Zhang, F.; Zhou, H.; Kam, W.; Wilson, B.; Hong, J.-S., Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson’s disease. *Environmental health perspectives* **2011**, *119*, (6), 807-814.

149. Rutherford, N. J.; Sacino, A. N.; Brooks, M.; Ceballos-Diaz, C.; Ladd, T. B.; Howard, J. K.; Golde, T. E.; Giasson, B. I., Studies of lipopolysaccharide effects on the induction of alpha-synuclein pathology by exogenous fibrils in transgenic mice. *Mol Neurodegener* **2015**, *10*, (1), 32.

150. Dutta, G.; Zhang, P.; Liu, B., The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery. *Fundam Clin Pharmacol* **2008**, *22*, (5), 453-64.

151. Nava Catorce, M.; Gevorkian, G., LPS-induced murine neuroinflammation model: main features and suitability for pre-clinical assessment of nutraceuticals. *Current neuropharmacology* **2016**, *14*, (2), 155-164.

152. Sheng, J. G.; Bora, S. H.; Xu, G.; Borchelt, D. R.; Price, D. L.; Koliatsos, V. E., Lipopolysaccharide-induced neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. *Neurobiology of disease* **2003**, *14*, (1), 133-45.

153. Faas, M. M.; Schuiling, G. A.; Baller, J. F.; Visscher, C. A.; Bakker, W. W., A new animal model for human preeclampsia: ultra-lowdose endotoxin infusion in pregnant rats. *American journal of obstetrics and gynecology* **1994**, *171*, (1), 158-164.

154. Kell, D. B.; Kenny, L. C., A Dormant Microbial Component in the Development of Preeclampsia. *Front Med (Lausanne)* **2016**, *3*, 60.

155. Kenny, L. C.; Kell, D. B., Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father. *Front Med (Lausanne)* **2017**, *4*, 239.

156. Kim, W.-G.; Mohney, R. P.; Wilson, B.; Jeohn, G.-H.; Liu, B.; Hong, J.-S., Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. *Journal of Neuroscience* **2000**, *20*, (16), 6309-6316.

157. Qin, L.; Liu, Y.; Wang, T.; Wei, S. J.; Block, M. L.; Wilson, B.; Liu, B.; Hong, J. S., NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. *J Biol Chem* **2004**, *279*, (2), 1415-21.

158. Kell, D. B.; Pretorius, E., On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-
induced cell death. *Integrative biology : quantitative biosciences from nano to macro* 2015, 7, (11), 1339-77.

159. Takeuchi, O.; Hoshino, K.; Kawai, T.; Sanjo, H.; Takada, H.; Ogawa, T.; Takeda, K.; Akira, S., Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. *Immunity* 1999, 11, (4), 443-51.

160. Muhammad, T.; Ikram, M.; Ullah, R.; Rehman, S. U.; Kim, M. O., Hesperetin, a Citrus Flavonoid, Attenuates LPS-Induced Neuroinflammation, Apoptosis and Memory Impairments by Modulating TLR4/NF-κB Signaling. *Nutrients* 2019, 11, (3).

161. Patel, H.; Fellowes, R.; Coade, S.; Woo, P., Human serum amyloid A has cytokine-like properties. *Scandinavian journal of immunology* 1998, 48, (4), 410-418.

162. Wispelwey, B.; Lesse, A. J.; Hansen, E. J.; Scheld, W. M., Haemophilus influenzae lipopolysaccharide-induced blood brain barrier permeability during experimental meningitis in the rat. *J Clin Invest* 1988, 82, (4), 1339-46.

163. Tomas-Camardiel, M.; Rite, I.; Herrera, A. J.; de Pablos, R. M.; Cano, J.; Machado, A.; Venero, J. L., Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. *Neurobiology of disease* 2004, 16, (1), 190-201.

164. Bohatschek, M.; Werner, A.; Raivich, G., Systemic LPS injection leads to granulocyte influx into normal and injured brain: effects of ICAM-1 deficiency. *Experimental neurology* 2001, 172, (1), 137-152.

165. Sumi, N.; Nishioku, T.; Takata, F.; Matsumoto, J.; Watanabe, T.; Shuto, H.; Yamauchi, A.; Dohgu, S.; Katoa, Y., Lipopolysaccharide-activated microglia induce dysfunction of the blood-brain barrier in rat microvascular endothelial cells co-cultured with microglia. *Cell Mol Neurobiol* 2010, 30, (2), 247-53.

166. di Penta, A.; Moreno, B.; Reix, S.; Fernandez-Diez, B.; Villanueva, M.; Errea, O.; Escala, N.; Vandenbroeck, K.; Comella, J. X.; Villoslada, P., Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. *PloS one* 2013, 8, (2), e54722.

167. Koprich, J. B.; Reske-Nielsen, C.; Mithal, P.; Isacson, O., Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. *J Neuroinflammation* 2008, 5, (1), 8.

168. Sui, Y. T.; Bullock, K. M.; Erickson, M. A.; Zhang, J.; Banks, W. A., Alpha synuclein is transported into and out of the brain by the blood-brain barrier. *Peptides* 2014, 62, 197-202.

169. Vekilov, P. G., Phase diagrams and kinetics of phase transitions in protein solutions. *J Phys Condens Matter* 2012, 24, (19), 193101.

170. Oosawa, F.; Kasi, M., A theory of linear and helical aggregations of macromolecules. *J Mol Biol* 1962, 4, 10-21.

171. Ruschak, A. M.; Miranker, A. D., Fiber-dependent amyloid formation as catalysis of an existing reaction pathway. *Proc Natl Acad Sci U S A* 2007, 104, (30), 12341-6.

172. Cohen, S. I.; Linse, S.; Luheishi, L. M.; Hellstrand, E.; White, D. A.; Rajah, L.; Otzen, D. E.; Vendruscolo, M.; Dobson, C. M.; Knowles, T. P., Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. *Proceedings of the National Academy of Sciences* 2013, 110, (24), 9758-9763.
173. Cohen, S. I.; Vendruscolo, M.; Dobson, C. M.; Knowles, T. P., Nucleated polymerization with secondary pathways. II. Determination of self-consistent solutions to growth processes described by non-linear master equations. *J Chem Phys* **2011**, 135, (6), 065106.

174. Luhrs, T.; Ritter, C.; Adrian, M.; Riek-Loher, D.; Bohrmann, B.; Dobeli, H.; Schubert, D.; Riek, R., 3D structure of Alzheimer’s amyloid-beta(1-42) fibrils. *Proc Natl Acad Sci U S A* **2005**, 102, (48), 17342-7.

175. Galvagnion, C.; Buell, A. K.; Meisl, G.; Michaels, T. C.; Vendruscolo, M.; Knowles, T. P.; Dobson, C. M., Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. *Nat Chem Biol* **2015**, 11, (3), 229-34.

176. Tomlinson, J. J.; Shutinoski, B.; Dong, L.; Meng, F.; Elleithy, D.; Lengacher, N. A.; Nguyen, A. P.; Cron, G. O.; Jiang, Q.; Roberson, E. D.; Nussbaum, R. L.; Majbour, N. K.; El-Agnaf, O. M.; Bennett, S. A.; Lagace, D. C.; Woulfe, J. M.; Sad, S.; Brown, E. G.; Schlossmacher, M. G., Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. *J Neural Transm (Vienna)* **2017**, 124, (6), 721-738.

177. Kumar, D. K.; Choi, S. H.; Washicosky, K. J.; Eimer, W. A.; Tucker, S.; Ghofrani, J.; Lefkowitz, A.; McColl, G.; Goldstein, L. E.; Tanzi, R. E.; Moir, R. D., Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. *Sci Transl Med* **2016**, 8, (340), 340ra72.

178. Park, S. C.; Moon, J. C.; Shin, S. Y.; Son, H.; Jung, Y. J.; Kim, N. H.; Kim, Y. M.; Jang, M. K.; Lee, J. R., Functional characterization of alpha-synuclein protein with antimicrobial activity. *Biochem Biophys Res Commun* **2016**, 478, (2), 924-8.

179. Pretorius, E.; Page, M. J.; Hendricks, L.; Nkosi, N. B.; Benson, S. R.; Kell, D. B., Both lipopolysaccharide and lipoteichoic acids potently induce anomalous fibrin amyloid formation: assessment with novel Amytracker™ stains. *Journal of The Royal Society Interface* **2018**, 15, (139), 20170941.

180. Kaur, T.; Uppoor, A.; Naik, D., Parkinson’s disease and periodontitis - the missing link? A review. *Gerodontology* **2016**, 33, (4), 434-438.

181. Pradeep, A. R.; Singh, S. P.; Martande, S. S.; Raju, A. P.; Rustagi, T.; Suve, D. K.; Naik, S. B., Clinical evaluation of the periodontal health condition and oral health awareness in Parkinson's disease patients. *Gerodontology* **2015**, 32, (2), 100-6.

182. Cicciu, M.; Risitano, G.; Lo Giudice, G.; Bramanti, E., Periodontal health and caries prevalence evaluation in patients affected by Parkinson’s disease. *Parkinsons Dis* **2012**, 2012, 541908.

183. Schwarz, J.; Heimhiller, E.; Storch, A., Increased periodontal pathology in Parkinson's disease. *J Neurol* **2006**, 253, (5), 608-11.

184. Liu, T. C.; Sheu, J. J.; Lin, H. C.; Jensen, D. A., Increased risk of parkinsonism following chronic periodontitis: a retrospective cohort study. *Mov Disord* **2013**, 28, (9), 1307-8.

185. Chen, C.-K.; Wu, Y.-T.; Chang, Y.-C., Periodontal inflammatory disease is associated with the risk of Parkinson’s disease: a population-based retrospective matched-cohort study. *Peeri* **2017**, 5, e3647.

186. Shanker, J.; Setty, P.; Arvind, P.; Nair, J.; Bhasker, D.; Balakrishna, G.; Kakkar, V. V., Relationship between periodontal disease, Porphyromonas gingivalis, peripheral vascular resistance markers and coronary artery disease in Asian Indians. *Thrombosis research* **2013**, 132, (1), e8-14.

187. Amar, S.; Engelke, M., Periodontal Innate Immune Mechanisms Relevant to Atherosclerosis. *Molecular oral microbiology* **2014**.
188. Singhrao, S. K.; Harding, A.; Simmons, T.; Robinson, S.; Kesavalu, L.; Crean, S., Oral inflammation, tooth loss, risk factors, and association with progression of Alzheimer's disease. *Journal of Alzheimer's disease: JAD 2014*, 42, (3), 723-37.

189. Dominy, S. S.; Lynch, C.; Ermini, F.; Benedyk, M.; Marczyk, A.; Konradi, A.; Nguyen, M.; Haditsch, U.; Raha, D.; Griffin, C.; Holsinger, L. J.; Arastu-Kapur, S.; Kaba, S.; Lee, A.; Ryder, M. I.; Potempa, B.; Mydel, P.; Hellvard, A.; Adamowicz, K.; Hasturk, H.; Walker, G. D.; Reynolds, E. C.; Faull, R. L. M.; Curtis, M. A.; Dragunow, M.; Potempa, J., Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. *Science advances 2019*, 5, (1), eaau3333.

190. Olsen, I.; Singhrao, S. K., Is there a link between genetic defects in the complement cascade and Porphyromonas gingivalis in Alzheimer's disease? *J Oral Microbiol 2020*, 12, (1), 1676486.

191. Nakajima, M.; Arimatsu, K.; Kato, T.; Matsuda, Y.; Minagawa, T.; Takahashi, N.; Ohno, H.; Yamazaki, K., Oral Administration of P. gingivalis Induces Dysbiosis of Gut Microbiota and Impaired Barrier Function Leading to Dissemination of Enterobacteria to the Liver. *Plos one 2015*, 10, (7), e0134234.

192. Arimatsu, K.; Yamada, H.; Miyazawa, H.; Minagawa, T.; Nakajima, M.; Ryder, M. I.; Gotoh, K.; Motooka, D.; Nakamura, S.; Iida, T.; Yamazaki, K., Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. *Sci Rep 2014*, 4, 4828.

193. Kato, T.; Yamazaki, K.; Nakajima, M.; Date, Y.; Kikuchi, J.; Hase, K.; Ohno, H.; Yamazaki, K., Oral Administration of Porphyromonas gingivalis Alters the Gut Microbiome and Serum Metabolome. *mSphere 2018*, 3, (5), e00460-18.

194. Nakajima, Y.; Ito, K.; Yoshimoto, T., Prolyl Tripeptidylpeptidase. In *Handbook of proteolytic enzymes*, Academic Press: 2013; Vol. 3, pp 3371-3374.

195. Dutta, S. K.; Verma, S.; Jain, V.; Surapaneni, B. K.; Vinayek, R.; Phillips, L.; Nair, P. P., Parkinson's Disease: The Emerging Role of Gut Dysbiosis, Antibiotics, Probiotics, and Fecal Microbiota Transplantation. *J Neurogastroenterol Motil 2019*, 25, (3), 363-376.

196. Barboza, J. L.; Okun, M. S.; Moshiree, B., The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease. *Expert Opin Pharmacother 2015*, 16, (16), 2449-64.

197. Barichella, M.; Pacchetti, C; Bolli, C; Cassani, E; Iorio, L; Pusani, C; Pinelli, G; Privitera, G; Cesari, I; Faierman, S; A; Caccilanza, R; Pezzoli, G; Cereda, E; Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. *Neurology 2016*, 87, (12), 1274-80.

198. Gazerani, P., Probiotics for Parkinson's Disease. *Int J Mol Sci 2019*, 20, (17).

199. Uyar, G.; Yildiran, H., A nutritional approach to microbiota in Parkinson’s disease. *Biosci Microbiota Food Health 2019*, 38, (4), 115-127.

200. Ramprasad, C; Douglas, J; Y.; Moshiree, B., Parkinson’s Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects. *Curr Treat Options Gastroenterol 2018*, 16, (4), 489-510.

201. Radad, K.; Moldzio, R.; Rausch, W. D., Minocycline protects dopaminergic neurons against long-term rotenone toxicity. *Can J Neurol Sci 2010*, 37, (1), 81-5.

202. Thomas, M; Le, W. D., Minocycline: neuroprotective mechanisms in Parkinson's disease. *Curr Pharm Des 2004*, 10, (6), 679-86.

203. Kim, H. S.; Suh, Y. H., Minocycline and neurodegenerative diseases. *Behav Brain Res 2009*, 196, (2), 168-79.
204. Diguet, E.; Fernagut, P. O.; Wei, X.; Du, Y.; Rouland, R.; Gross, C.; Bezard, E.; Tison, F., Deleterious effects of minocycline in animal models of Parkinson’s disease and Huntington’s disease. *Eur J Neurosci* 2004, 19, (12), 3266-76.

205. Yulug, B.; Hanoglu, L.; Kilic, E.; Schabitz, W. R., RIFAMPICIN: an antibiotic with brain protective function. *Brain Res Bull* 2014, 107, 37-42.

206. Bi, W.; Zhu, L.; Jing, X.; Liang, Y.; Tao, E., Rifampicin and Parkinson’s disease. *Neurol Sci* 2013, 34, (2), 137-41.

207. Acuña, L.; Hamadat, S.; Corbalán, N. S.; González-Lizárraga, F.; Dos-Santos-Pereira, M.; Rocca, J.; Díaz, J. S.; Del-Bel, E.; Papy-García, D.; Chehin, R. N.; Michel, P. P.; Raisman-Vozari, R., Rifampicin and Its Derivative Rifampicin Quinone Reduce Microglial Inflammatory Responses and Neurodegeneration Induced In Vitro by α-Synuclein Fibrillary Aggregates. *Cells* 2019, 8, (8).

208. Lin, D.; Jing, X.; Chen, Y.; Liang, Y.; Lei, M.; Peng, S.; Zhou, T.; Zheng, D.; Zeng, Z.; Wu, X.; Yang, L.; Xiao, S.; Liu, J.; Tao, E., Rifampicin pre-treatment inhibits the toxicity of rotenone-induced PC12 cells by enhancing sumoylation modification of α-synuclein. *Biochem Biophys Res Commun* 2017, 485, (1), 23-29.

209. Henley, J. M.; Carmichael, R. E.; Wilkinson, K. A., Extraneuronal SUMOylation in Neurons. *Trends Neurosci* 2018, 41, (4), 198-210.

210. Guerra de Souza, A. C.; Prediger, R. D.; Cimarosti, H., SUMO-regulated mitochondrial function in Parkinson’s disease. *J Neurochem* 2016, 137, (5), 673-86.

211. Mertsalmi, T. H.; Pekkonen, E.; Scheperjans, F., Antibiotic exposure and risk of Parkinson’s disease in Finland: A nationwide case-control study. *Mov Disord 2020*, 35, (3), 431-442.

212. Devos, D.; Moreau, C.; Devedjian, J. C.; Kluza, J.; Petrault, M.; Laloux, C.; Jonneaux, A.; Ryckewaert, G.; Garçon, G.; Rouaix, N., Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. *Antioxidants & redox signaling* 2014, 21, (2), 195-210.

213. Jomova, K.; Valko, M., Importance of iron chelation in free radical-induced oxidative stress and human disease. *Curr Pharm Des* 2011, 17, (31), 3460-73.

214. Zecca, L.; Casella, L.; Albertini, A.; Bellei, C.; Zucca, F. A.; Engelen, M.; Zadlo, A.; Szewczyk, G.; Zareba, M.; Sarna, T., Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease. *Journal of neurochemistry* 2008, 106, (4), 1866-1875.

215. Mandel, S.; Maor, G.; Youdim, M. B., Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. *J Mol Neurosci* 2004, 24, (3), 401-16.

216. Youdim, M. B. H.; Stephenson, G.; Shachar, D. B., Ironing iron out in Parkinson’s disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. *Annals of the New York Academy of Sciences* 2004, 1012, (1), 306-325.

217. Bar-Am, O.; Amit, T.; Kupershmidt, L.; Aluf, Y.; Mechlovich, D.; Kabha, H.; Danovitch, L.; Zurawski, V. R.; Youdim, M. B.; Weinreb, O., Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson’s disease and aging. *Neurobiol Aging* 2015, 36, (3), 1529-42.

218. Nuñez, M. T.; Urrutia, P.; Mena, N.; Aguirre, P.; Tapia, V.; Salazar, J., Iron toxicity in neurodegeneration. *Biometa* 2012, 25, (4), 761-76.
219. Nuñez, M. T.; Chana-Cuevas, P., New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases. *Pharmaceuticals (Basel)* **2018**, 11, (4), 109.

220. Youdim, M.; Fridkin, M.; Zheng, H., Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson’s disease and other neurodegenerative diseases. *Journal of neural transmission* **2004**, 111, (10-11), 1455-1471.

221. Li, Q.; Wan, J.; Lan, X.; Han, X.; Wang, Z.; Wang, J., Neuroprotection of brain-permeable iron chelator VK-28 against intracerebral hemorrhage in mice. *J Cereb Blood Flow Metab* **2017**, 37, (9), 3110-3123.

222. Martin-Bastida, A.; Ward, R. J.; Newbould, R.; Piccini, P.; Sharp, D.; Khabba, C.; Patel, M. C.; Spino, M.; Connelly, J.; Tricta, F.; Crichton, R. R.; Dexter, D. T., Brain iron chelation by deferiprone in a phase 2 randomised double-blind placebo controlled clinical trial in Parkinson’s disease. *Sci Rep* **2017**, 7, (1), 1398.

223. Klopotock, T.; Tricta, F.; Neumayr, L.; Karin, I.; Zorzi, G.; Fradette, C.; Kmieć, T.; Büchner, B.; Steele, H. E.; Horvath, R.; Chinnery, P. F.; Basu, A.; Küpper, C.; Neuhofer, C.; Kálmán, B.; Dušek, P.; Yapici, Z.; Wilson, I.; Zhao, F.; Zibordi, F.; Nardocci, N.; Ayala, C.; Hayflick, S. J.; Spino, M.; Blamire, A. M.; Hogarth, P.; Vichinsky, E., Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. *Lancet Neurol* **2019**, 18, (7), 631-642.

224. Levites, Y.; Weinreb, O.; Maor, G.; Youdim, M. B.; Mandel, S., Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. *J Neurochem* **2001**, 78, (5), 1073-82.

225. Ghosh, B.; Antonio, T.; Reith, M. E.; Dutta, A. K., Discovery of 4-(4-((5-Hydroxy-1, 2, 3, 4-tetrahydroquinolin-8-yl)quinolin-1-yl)ethoxy)-piperazin-1-yl)propyl) piperazin-1-yl) quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson’s disease. *Journal of medicinal chemistry* **2010**, 53, (5), 2114-2125.

226. Aguirre, P.; Garcia-Beltran, O.; Tapia, V.; Munoz, Y.; Cassels, B. K.; Nunez, M. T., Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe(2+)/Cu(2+) Chelator in Cell and Animal Models of Parkinson’s Disease. *ACS Chem Neurosci* **2017**, 8, (1), 178-185.

227. Garcia-Beltran, O.; Mena, N. P.; Aguirre, P.; Barriga-Gonzalez, G.; Galdamez, A.; Nagles, E.; Adasme, T.; Hidalgo, C.; Nunez, M. T., Development of an iron-selective antioxidant probe with protective effects on neuronal function. *PloS one* **2017**, 12, (12), e0189043.

228. Borodina, I.; Kenny, L. C.; McCarthy, C. M.; Paramasivan, K.; Pretorius, E.; Roberts, T. J.; van der Hoek, S. A.; Kell, D. B., The biology of ergothioneine, an antioxidant nutraceutical. *Nutr Res Rev* **2020**, 1, 1-28.

229. Vaiserman, A. M.; Koliada, A. K.; Marotta, F., Gut microbiota: A player in aging and a target for anti-aging intervention. *Ageing Res Rev* **2017**, 35, 36-45.

230. Endres, K.; Schäfer, K. H., Influence of Commensal Microbiota on the Enteric Nervous System and Its Role in Neurodegenerative Diseases. *J Innate Immun* **2018**, 10, (3), 172-180.

231. Huang, H.; Xu, H.; Luo, Q.; He, J.; Li, M.; Chen, H.; Tang, W.; Nie, Y.; Zhou, Y., Fecal microbiota transplantation to treat Parkinson’s disease with constipation: A case report. *Medicine (Baltimore)* **2019**, 98, (26), e16163.
232. Sun, M. F.; Zhu, Y. L.; Zhou, Z. L.; Jia, X. B.; Xu, Y. D.; Yang, Q.; Cui, C.; Shen, Y. Q., Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-alpha signaling pathway. *Brain Behav Immun* 2018, 70, 48-60.

233. Nguyen, S. V.; Nguyen, M. T. H.; Tran, B. C.; Ho, M. T. Q.; Umeda, K.; Rahman, S., Evaluation of lozenges containing egg yolk antibody against Porphyromonas gingivalis gingipains as an adjunct to conventional non-surgical therapy in periodontitis patients: A randomized controlled clinical trial. *J Periodontol* 2018, 89, (11), 1334-1339.

234. Cuello, A. C., Ted Sourkes, Moussa Youdim and I. *J Neural Transm (Vienna)* 2020, 127, (2), 119-123.